<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Fexofenadine - Complete Drug Monograph</title>
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/css/bootstrap.min.css" rel="stylesheet">
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/gsap/3.12.2/gsap.min.js"></script>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: #1a202c;
            line-height: 1.8;
            overflow-x: hidden;
        }

        .main-container {
            max-width: 1400px;
            margin: 0 auto;
            padding: 20px;
        }

        .header-banner {
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
            color: white;
            padding: 50px 40px;
            border-radius: 25px;
            margin-bottom: 30px;
            box-shadow: 0 20px 60px rgba(0,0,0,0.3);
            text-align: center;
        }

        .header-banner h1 {
            font-size: 3em;
            font-weight: 900;
            margin-bottom: 15px;
            text-shadow: 3px 3px 6px rgba(0,0,0,0.3);
        }

        .header-banner p {
            font-size: 1.3em;
            opacity: 0.95;
            font-weight: 500;
        }

        .nav-box {
            background: linear-gradient(135deg, #ffecd2 0%, #fcb69f 100%);
            padding: 30px;
            border-radius: 25px;
            margin-bottom: 30px;
            box-shadow: 0 15px 45px rgba(0,0,0,0.2);
        }

        .nav-box h3 {
            color: #2d3748;
            font-weight: 800;
            margin-bottom: 20px;
            font-size: 1.8em;
            text-align: center;
        }

        .nav-links {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(220px, 1fr));
            gap: 12px;
        }

        .nav-link {
            background: linear-gradient(135deg, #ffffff 0%, #f7fafc 100%);
            padding: 12px 18px;
            border-radius: 15px;
            text-decoration: none;
            color: #2d3748;
            font-weight: 600;
            font-size: 0.9em;
            transition: all 0.3s ease;
            text-align: center;
            box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            border: 2px solid transparent;
            display: block;
        }

        .nav-link:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            transform: translateY(-3px);
            box-shadow: 0 8px 25px rgba(102,126,234,0.4);
            border-color: #667eea;
        }

        .content-section {
            background: white;
            padding: 40px;
            border-radius: 25px;
            margin-bottom: 30px;
            box-shadow: 0 15px 40px rgba(0,0,0,0.15);
            animation: fadeInUp 0.7s ease-out;
        }

        @keyframes fadeInUp {
            from {
                opacity: 0;
                transform: translateY(40px);
            }
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }

        .section-header {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 20px 30px;
            border-radius: 15px;
            margin: -40px -40px 30px -40px;
            font-size: 1.9em;
            font-weight: 800;
            box-shadow: 0 8px 20px rgba(102,126,234,0.3);
        }

        .warning-box {
            background: linear-gradient(135deg, #fc5c7d 0%, #6a82fb 100%);
            color: white;
            padding: 30px;
            border-radius: 20px;
            border-left: 8px solid #e53e3e;
            margin: 25px 0;
            box-shadow: 0 10px 30px rgba(252,92,125,0.3);
        }

        .warning-box h4 {
            font-size: 1.5em;
            margin-bottom: 15px;
            font-weight: 800;
        }

        .info-box {
            background: linear-gradient(135deg, #a8edea 0%, #fed6e3 100%);
            padding: 25px;
            border-radius: 18px;
            margin: 20px 0;
            border-left: 6px solid #3182ce;
            box-shadow: 0 6px 20px rgba(168,237,234,0.3);
            color: #1a202c;
        }

        .success-box {
            background: linear-gradient(135deg, #d4fc79 0%, #96e6a1 100%);
            padding: 25px;
            border-radius: 18px;
            margin: 20px 0;
            border-left: 6px solid #38a169;
            box-shadow: 0 6px 20px rgba(150,230,161,0.3);
            color: #1a202c;
        }

        .data-table {
            width: 100%;
            margin: 25px 0;
            border-collapse: separate;
            border-spacing: 0;
            overflow: hidden;
            border-radius: 15px;
            box-shadow: 0 8px 25px rgba(0,0,0,0.12);
        }

        .data-table thead {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
        }

        .data-table th {
            padding: 18px;
            font-weight: 800;
            text-align: left;
            font-size: 1.05em;
        }

        .data-table td {
            padding: 15px 18px;
            border-bottom: 1px solid #e2e8f0;
            font-size: 0.95em;
            color: #2d3748;
        }

        .data-table tbody tr:nth-child(even) {
            background: #f8f9fa;
        }

        .data-table tbody tr:hover {
            background: #edf2f7;
            transition: background 0.3s ease;
        }

        .chart-container {
            margin: 30px 0;
            padding: 25px;
            background: linear-gradient(135deg, #ffecd2 0%, #fcb69f 100%);
            border-radius: 18px;
            box-shadow: 0 8px 25px rgba(0,0,0,0.1);
        }

        .myth-section {
            background: linear-gradient(135deg, #fa709a 0%, #fee140 100%);
            padding: 40px;
            border-radius: 25px;
            margin-bottom: 30px;
            box-shadow: 0 15px 45px rgba(250,112,154,0.3);
        }

        .myth-header {
            font-size: 2.2em;
            color: #2d3748;
            font-weight: 900;
            margin-bottom: 25px;
            text-align: center;
            text-shadow: 2px 2px 4px rgba(0,0,0,0.1);
        }

        .myth-item {
            background: white;
            padding: 20px 25px;
            border-radius: 15px;
            margin: 15px 0;
            border-left: 6px solid #fc5c7d;
            font-weight: 700;
            font-size: 1.05em;
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
            color: #1a202c;
        }

        .truth-item {
            background: white;
            padding: 20px 25px;
            border-radius: 15px;
            margin: 15px 0;
            border-left: 6px solid #48bb78;
            font-weight: 600;
            font-size: 1.05em;
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
            color: #1a202c;
        }

        ul, ol {
            margin: 20px 0;
            padding-left: 30px;
        }

        li {
            margin: 10px 0;
            font-size: 0.98em;
            line-height: 1.7;
            color: #2d3748;
        }

        strong {
            color: #2d3748;
            font-weight: 800;
        }

        h3 {
            color: #2d3748;
            font-weight: 800;
            margin: 25px 0 15px 0;
            font-size: 1.6em;
        }

        h4 {
            color: #4a5568;
            font-weight: 700;
            margin: 20px 0 12px 0;
            font-size: 1.3em;
        }

        p {
            color: #2d3748;
            margin: 10px 0;
        }

        @media (max-width: 768px) {
            body {
                font-size: 0.88em;
            }

            .main-container {
                padding: 12px;
            }

            .header-banner h1 {
                font-size: 2em;
            }

            .header-banner {
                padding: 30px 25px;
            }

            .header-banner p {
                font-size: 1em;
            }

            .content-section {
                padding: 25px;
            }

            .section-header {
                font-size: 1.4em;
                padding: 15px 20px;
                margin: -25px -25px 25px -25px;
            }

            .nav-links {
                grid-template-columns: repeat(2, 1fr);
                gap: 10px;
            }

            .nav-link {
                font-size: 0.78em;
                padding: 10px 12px;
            }

            .data-table {
                font-size: 0.82em;
            }

            .data-table th, .data-table td {
                padding: 10px 8px;
            }

            .chart-container {
                padding: 20px;
            }

            h3 {
                font-size: 1.35em;
            }

            h4 {
                font-size: 1.15em;
            }

            .warning-box, .info-box, .success-box {
                padding: 20px;
            }
        }
    </style>
</head>
<body>
    <div class="main-container">
        
        <!-- Header Banner -->
        <div class="header-banner">
            <h1>üíä FEXOFENADINE</h1>
            <p>Complete Drug Monograph | Non-Sedating Antihistamine</p>
        </div>

        <!-- Quick Navigation Box -->
        <div class="nav-box">
            <h3>üß≠ Quick Navigation</h3>
            <div class="nav-links">
                <a href="#section1" class="nav-link">1. Black Box Warning</a>
                <a href="#section2" class="nav-link">2. History & Nomenclature</a>
                <a href="#section3" class="nav-link">3. Drug Classification</a>
                <a href="#section4" class="nav-link">4. Latest News & Updates</a>
                <a href="#section5" class="nav-link">5. Clinical Indications</a>
                <a href="#section6" class="nav-link">6. Age-Specific Guidelines</a>
                <a href="#section7" class="nav-link">7. Administration Guidelines</a>
                <a href="#section8" class="nav-link">8. Dosing Parameters</a>
                <a href="#section9" class="nav-link">9. Missed Dose Management</a>
                <a href="#section10" class="nav-link">10. Drug Conversion</a>
                <a href="#section11" class="nav-link">11. Clinical Efficacy Data</a>
                <a href="#section12" class="nav-link">12. Mechanism of Action</a>
                <a href="#section13" class="nav-link">13. Contraindications</a>
                <a href="#section14" class="nav-link">14. Drug Interactions</a>
                <a href="#section15" class="nav-link">15. Adverse Effects</a>
                <a href="#section16" class="nav-link">16. Patient Concerns</a>
                <a href="#section17" class="nav-link">17. Case Reports</a>
                <a href="#section18" class="nav-link">18. Pregnancy & Preconception</a>
                <a href="#section19" class="nav-link">19. Lactation & Breastfeeding</a>
                <a href="#section20" class="nav-link">20. Safety Monitoring</a>
                <a href="#section21" class="nav-link">21. Storage & Handling</a>
                <a href="#section22" class="nav-link">22. Prolonged Use Effects</a>
                <a href="#section23" class="nav-link">23. Nutritional Support</a>
                <a href="#section24" class="nav-link">24. Side Effect Management</a>
                <a href="#section25" class="nav-link">25. Dermatological Issues</a>
                <a href="#section26" class="nav-link">26. Special Populations</a>
                <a href="#section27" class="nav-link">27. Laboratory Profile</a>
                <a href="#section28" class="nav-link">28. Pipeline & Future Drugs</a>
                <a href="#section29" class="nav-link">29. Data Visualization</a>
                <a href="#section30" class="nav-link">30. Technical Specifications</a>
                <a href="#myths" class="nav-link">üîç Common Myths</a>
            </div>
        </div>

        <!-- SECTION 1: Black Box Warning -->
        <div id="section1" class="content-section">
            <h2 class="section-header">‚ö†Ô∏è 1. BLACK BOX WARNING</h2>
            
            <!-- img -->
            
            <div class="warning-box">
                <h4>‚ö†Ô∏è IMPORTANT SAFETY NOTICE</h4>
                <p><strong>Note:</strong> Fexofenadine does NOT carry a Black Box Warning from the FDA.</p>
                <p>This medication has an excellent safety profile with over 25 years of clinical use.</p>
            </div>

            <h3>Critical Safety Alerts</h3>
            <div class="info-box">
                <ul>
                    <li><strong>Renal Impairment:</strong> Dose adjustment required in decreased kidney function</li>
                    <li><strong>Fruit Juice Interaction:</strong> AVOID apple, orange, grapefruit juice - reduces absorption by 36-70%</li>
                    <li><strong>Cardiac Caution:</strong> Use carefully in patients with QT prolongation risk factors</li>
                    <li><strong>Hypersensitivity:</strong> Rare serious reactions including Stevens-Johnson syndrome</li>
                </ul>
            </div>

            <h4>Risk Mitigation Strategies</h4>
            <ul>
                <li>Start lower doses in elderly and renally impaired patients</li>
                <li>Take ONLY with water, never with fruit juices</li>
                <li>Monitor for allergic reaction signs</li>
                <li>Avoid combining with QT-prolonging medications</li>
            </ul>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 2: History and Nomenclature -->
        <div id="section2" class="content-section">
            <h2 class="section-header">üìö 2. HISTORY AND NOMENCLATURE</h2>
            
            <!-- img -->

            <h3>Drug Names and Etymology</h3>
            <div class="success-box">
                <p><strong>Generic Name:</strong> Fexofenadine</p>
                <p><strong>Brand Names:</strong> Allegra, Telfast, Fexo, Altiva, Fastofen</p>
                <p><strong>Chemical Name:</strong> 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-Œ±,Œ±-dimethylbenzeneacetic acid</p>
                <p><strong>Etymology:</strong> Derived from parent compound terfenadine, modified to create active metabolite</p>
            </div>

            <h3>Historical Development Timeline</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Year</th>
                        <th>Major Milestone</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>1996</td>
                        <td>FDA approval for seasonal allergic rhinitis</td>
                    </tr>
                    <tr>
                        <td>2000</td>
                        <td>Approval for chronic idiopathic urticaria</td>
                    </tr>
                    <tr>
                        <td>2002</td>
                        <td>Pediatric approval (6 months and older)</td>
                    </tr>
                    <tr>
                        <td>2011</td>
                        <td>Available over-the-counter in USA</td>
                    </tr>
                    <tr>
                        <td>2024</td>
                        <td>25-year clinical experience milestone</td>
                    </tr>
                </tbody>
            </table>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 3: Drug Classification -->
        <div id="section3" class="content-section">
            <h2 class="section-header">üè∑Ô∏è 3. DRUG CLASSIFICATION AND CATEGORY</h2>
            
            <!-- img -->

            <h3>Therapeutic Classification</h3>
            <div class="info-box">
                <p><strong>Therapeutic Class:</strong> Antihistamine</p>
                <p><strong>Pharmacological Category:</strong> Second-Generation H1-Receptor Inverse Agonist</p>
                <p><strong>ATC Code:</strong> R06AX26</p>
            </div>

            <h3>Classification Tree</h3>
            <div class="success-box">
                <pre style="font-family: monospace; line-height: 2; color: #2d3748;">
üì¶ <strong>ANTIHISTAMINES</strong>
    ‚îú‚îÄ‚îÄ First-Generation (Sedating)
    ‚îÇ   ‚îú‚îÄ‚îÄ Diphenhydramine
    ‚îÇ   ‚îú‚îÄ‚îÄ Chlorpheniramine
    ‚îÇ   ‚îî‚îÄ‚îÄ Promethazine
    ‚îî‚îÄ‚îÄ Second-Generation (Non-Sedating)
        ‚îú‚îÄ‚îÄ <strong>Fexofenadine ‚≠ê</strong>
        ‚îú‚îÄ‚îÄ Loratadine
        ‚îú‚îÄ‚îÄ Desloratadine
        ‚îú‚îÄ‚îÄ Cetirizine
        ‚îî‚îÄ‚îÄ Levocetirizine
                </pre>
            </div>

            <h3>All Drug Forms and Salts</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Form/Salt</th>
                        <th>Strengths Available</th>
                        <th>Bioavailability</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Fexofenadine Hydrochloride Tablets</strong></td>
                        <td>30mg, 60mg, 120mg, 180mg</td>
                        <td>~33%</td>
                    </tr>
                    <tr>
                        <td>Orally Disintegrating Tablets (ODT)</td>
                        <td>30mg</td>
                        <td>~33%</td>
                    </tr>
                    <tr>
                        <td>Oral Suspension</td>
                        <td>30mg/5mL</td>
                        <td>~35%</td>
                    </tr>
                    <tr>
                        <td>Combination (with Pseudoephedrine)</td>
                        <td>60mg/120mg, 180mg/240mg</td>
                        <td>Variable</td>
                    </tr>
                </tbody>
            </table>

            <h3>Related Medications in Same Category</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Drug Name</th>
                        <th>Primary Uses</th>
                        <th>Key Differences</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Loratadine</td>
                        <td>Allergic rhinitis, urticaria</td>
                        <td>Once daily, less potent</td>
                    </tr>
                    <tr>
                        <td>Desloratadine</td>
                        <td>Allergic rhinitis, urticaria</td>
                        <td>Active metabolite, more potent</td>
                    </tr>
                    <tr>
                        <td>Cetirizine</td>
                        <td>Allergic rhinitis, urticaria</td>
                        <td>Slight sedation possible</td>
                    </tr>
                    <tr>
                        <td>Levocetirizine</td>
                        <td>Allergic rhinitis, urticaria</td>
                        <td>R-enantiomer, more selective</td>
                    </tr>
                </tbody>
            </table>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 4: Latest News -->
        <div id="section4" class="content-section">
            <h2 class="section-header">üì∞ 4. LATEST NEWS AND GUIDELINES UPDATES</h2>
            
            <!-- img -->

            <h3>Recent FDA Updates (2024-2025)</h3>
            <div class="success-box">
                <ul>
                    <li><strong>2024:</strong> 25-year clinical experience review published</li>
                    <li><strong>2024:</strong> Updated high-dose guidance (up to 540mg/day) for refractory chronic urticaria</li>
                    <li><strong>2025:</strong> New packaging updates for 60mg and 120mg tablets</li>
                    <li><strong>2025:</strong> Expanded coverage in New Zealand and UK healthcare systems</li>
                </ul>
            </div>

            <h3>Professional Organization Recommendations</h3>
            
            <h4>American Academy of Allergy, Asthma & Immunology (AAAAI)</h4>
            <div class="info-box">
                <p>Recommends second-generation antihistamines as first-line for allergic rhinitis and chronic urticaria. Fexofenadine preferred for non-sedating profile.</p>
            </div>

            <h4>World Allergy Organization (WAO)</h4>
            <div class="info-box">
                <p><strong>2024 Guidelines:</strong> Support updosing second-generation antihistamines up to 4x standard dose before adding additional therapies.</p>
            </div>

            <h4>European Academy of Allergy and Clinical Immunology (EAACI)</h4>
            <div class="info-box">
                <p>Endorse fexofenadine as truly non-sedating, suitable for patients requiring alertness.</p>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 5: Clinical Indications -->
        <div id="section5" class="content-section">
            <h2 class="section-header">üéØ 5. CLINICAL INDICATIONS</h2>
            
            <!-- img -->

            <h3>FDA-Approved Indications</h3>
            
            <h4>Seasonal Allergic Rhinitis (SAR)</h4>
            <div class="success-box">
                <p><strong>Population:</strong> Adults & Children ‚â•2 years</p>
                <p><strong>Symptoms Treated:</strong> Sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes</p>
                <p><strong>Standard Dosing:</strong></p>
                <ul>
                    <li>Adults & ‚â•12 years: 60mg BID or 180mg once daily</li>
                    <li>Children 2-11 years: 30mg BID</li>
                    <li>Children 6 months-2 years: 15mg BID</li>
                </ul>
            </div>

            <h4>Perennial Allergic Rhinitis (PAR)</h4>
            <div class="success-box">
                <p>Same population and dosing as SAR. For year-round allergies from dust mites, pet dander, mold.</p>
            </div>

            <h4>Chronic Idiopathic Urticaria (CIU)</h4>
            <div class="success-box">
                <p><strong>Population:</strong> Adults & Children ‚â•6 months</p>
                <p><strong>Treatment:</strong> Uncomplicated skin manifestations</p>
                <p><strong>High-Dose Option:</strong> Up to 540mg/day for refractory cases</p>
            </div>

            <h3>Off-Label Uses</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Condition</th>
                        <th>Evidence Level</th>
                        <th>Typical Dosing</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Chronic Spontaneous Urticaria</td>
                        <td>Strong</td>
                        <td>180-540mg/day</td>
                    </tr>
                    <tr>
                        <td>Physical Urticarias</td>
                        <td>Moderate</td>
                        <td>180-360mg/day</td>
                    </tr>
                    <tr>
                        <td>Cholinergic Urticaria</td>
                        <td>Moderate</td>
                        <td>180mg/day</td>
                    </tr>
                    <tr>
                        <td>Dermographism</td>
                        <td>Moderate</td>
                        <td>180mg/day</td>
                    </tr>
                </tbody>
            </table>

            <h3>Contraindicated Conditions</h3>
            <div class="warning-box">
                <h4>‚ùå Do NOT Use In:</h4>
                <ul>
                    <li>Known hypersensitivity to fexofenadine</li>
                    <li>Severe renal impairment (CrCl < 10 mL/min) without dose adjustment</li>
                    <li>Infants under 6 months</li>
                </ul>
            </div>

            <!-- img -->

            <div class="chart-container">
                <canvas id="indicationsChart"></canvas>
            </div>

            <!-- video -->
        </div>

        <!-- SECTION 6: Age-Specific Guidelines -->
        <div id="section6" class="content-section">
            <h2 class="section-header">üë• 6. AGE-SPECIFIC USAGE GUIDELINES</h2>
            
            <!-- img -->

            <h3>Adult Dosing Protocols</h3>
            <div class="success-box">
                <p><strong>Standard Adult Dose (‚â•12 years):</strong></p>
                <ul>
                    <li>60mg twice daily OR</li>
                    <li>180mg once daily</li>
                    <li>Take on empty stomach with water</li>
                </ul>
            </div>

            <h3>Pediatric Guidelines</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Age Group</th>
                        <th>Standard Dose</th>
                        <th>Maximum Daily Dose</th>
                        <th>Rationale</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>6 months - 2 years</td>
                        <td>15mg BID (oral suspension)</td>
                        <td>30mg/day</td>
                        <td>Body weight-adjusted dosing</td>
                    </tr>
                    <tr>
                        <td>2-11 years</td>
                        <td>30mg BID</td>
                        <td>60mg/day</td>
                        <td>Pediatric pharmacokinetics</td>
                    </tr>
                    <tr>
                        <td>‚â•12 years</td>
                        <td>60mg BID or 180mg QD</td>
                        <td>180mg/day</td>
                        <td>Adult dosing applies</td>
                    </tr>
                    <tr>
                        <td>< 6 months</td>
                        <td>NOT RECOMMENDED</td>
                        <td>N/A</td>
                        <td>Insufficient safety data</td>
                    </tr>
                </tbody>
            </table>

            <h3>Geriatric Considerations</h3>
            <div class="info-box">
                <p><strong>Elderly (‚â•65 years):</strong></p>
                <ul>
                    <li>Same standard dosing as adults</li>
                    <li>Consider starting at 60mg once daily in frail elderly</li>
                    <li>Monitor renal function - adjust if impaired</li>
                    <li>No increased risk of adverse effects vs younger adults</li>
                </ul>
            </div>

            <h3>Renal Impairment Dosing</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Renal Function</th>
                        <th>Recommended Dose</th>
                        <th>Frequency</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Normal (CrCl > 80)</td>
                        <td>60mg BID or 180mg QD</td>
                        <td>Standard</td>
                    </tr>
                    <tr>
                        <td>Mild (CrCl 50-80)</td>
                        <td>60mg BID or 180mg QD</td>
                        <td>No adjustment needed</td>
                    </tr>
                    <tr>
                        <td>Moderate (CrCl 30-50)</td>
                        <td>60mg once daily</td>
                        <td>Reduced frequency</td>
                    </tr>
                    <tr>
                        <td>Severe (CrCl < 30)</td>
                        <td>60mg once daily</td>
                        <td>Start low, monitor</td>
                    </tr>
                </tbody>
            </table>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 7: Administration Guidelines -->
        <div id="section7" class="content-section">
            <h2 class="section-header">üíâ 7. DRUG ADMINISTRATION GUIDELINES</h2>
            
            <!-- img -->

            <h3>Routes of Administration</h3>
            <div class="success-box">
                <p><strong>Primary Route:</strong> Oral (PO)</p>
                <p><strong>Available Forms:</strong> Tablets, ODT, Oral Suspension</p>
            </div>

            <h3>Step-by-Step Instructions</h3>
            
            <h4>For Standard Tablets:</h4>
            <ol>
                <li>Take on EMPTY STOMACH (2 hours after food)</li>
                <li>Swallow with WATER ONLY (never fruit juice)</li>
                <li>Do not split, crush, or chew tablets</li>
                <li>Best timing: Morning before breakfast or bedtime</li>
            </ol>

            <h4>For Orally Disintegrating Tablets (ODT):</h4>
            <ol>
                <li>Remove from blister pack immediately before use</li>
                <li>Place tablet on tongue</li>
                <li>Allow to disintegrate (30-60 seconds)</li>
                <li>Swallow with saliva (no water needed)</li>
            </ol>

            <h4>For Oral Suspension:</h4>
            <ol>
                <li>Shake bottle vigorously for 10 seconds</li>
                <li>Measure exact dose using provided measuring device</li>
                <li>Administer on empty stomach if possible</li>
                <li>Refrigerate after opening</li>
            </ol>

            <h3>CRITICAL: Food & Juice Interactions</h3>
            <div class="warning-box">
                <h4>‚ö†Ô∏è AVOID THESE BEVERAGES</h4>
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Substance</th>
                            <th>Effect</th>
                            <th>Action</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>üçé Apple Juice</td>
                            <td>‚Üì 71% absorption</td>
                            <td>Avoid completely</td>
                        </tr>
                        <tr>
                            <td>üçä Orange Juice</td>
                            <td>‚Üì 68% absorption</td>
                            <td>Avoid completely</td>
                        </tr>
                        <tr>
                            <td>üçá Grapefruit Juice</td>
                            <td>‚Üì 42% absorption</td>
                            <td>Avoid completely</td>
                        </tr>
                        <tr>
                            <td>üçî High-Fat Meals</td>
                            <td>‚Üì 21% absorption</td>
                            <td>Take 2h before/after</td>
                        </tr>
                        <tr>
                            <td>üíß Water</td>
                            <td>No effect</td>
                            <td>‚úÖ RECOMMENDED</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <h3>Optimal Timing</h3>
            <div class="info-box">
                <ul>
                    <li><strong>Best Time:</strong> Morning on empty stomach</li>
                    <li><strong>Alternative:</strong> Bedtime (2+ hours after dinner)</li>
                    <li><strong>Twice Daily:</strong> Morning & evening, 12 hours apart</li>
                    <li><strong>Consistency:</strong> Same time daily for best results</li>
                </ul>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 8: Dosing Parameters -->
        <div id="section8" class="content-section">
            <h2 class="section-header">üìä 8. DOSING PARAMETERS</h2>
            
            <!-- img -->

            <h3>Maximum Treatment Duration</h3>
            <div class="success-box">
                <p><strong>Long-Term Use:</strong> Acceptable and safe</p>
                <p><strong>No Time Limit:</strong> Can be used continuously for years if needed</p>
                <p><strong>Monitoring:</strong> Periodic clinical assessment recommended</p>
            </div>

            <h3>Maximum Daily Dose Guidelines</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Population</th>
                        <th>Standard Max Dose</th>
                        <th>High-Dose Protocol (Off-Label)</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Adults & Children ‚â•12 years</td>
                        <td>180mg/day</td>
                        <td>Up to 540mg/day for refractory urticaria</td>
                    </tr>
                    <tr>
                        <td>Children 2-11 years</td>
                        <td>60mg/day</td>
                        <td>Up to 120mg/day (specialist guidance)</td>
                    </tr>
                    <tr>
                        <td>Children 6 months-2 years</td>
                        <td>30mg/day</td>
                        <td>Not recommended</td>
                    </tr>
                    <tr>
                        <td>Renal Impairment</td>
                        <td>60mg/day</td>
                        <td>Not recommended</td>
                    </tr>
                </tbody>
            </table>

            <h3>Dose Escalation Protocol</h3>
            <div class="info-box">
                <h4>For Refractory Chronic Urticaria:</h4>
                <ol>
                    <li><strong>Week 1-2:</strong> Start 180mg once daily</li>
                    <li><strong>Week 3-4:</strong> If inadequate response, increase to 180mg BID (360mg/day)</li>
                    <li><strong>Week 5+:</strong> If still inadequate, increase to 180mg TID (540mg/day)</li>
                    <li><strong>Reassess:</strong> Every 4 weeks for efficacy and tolerability</li>
                </ol>
            </div>

            <h3>Dose De-escalation</h3>
            <div class="info-box">
                <ul>
                    <li>After symptom control for 3+ months, attempt gradual reduction</li>
                    <li>Decrease by one dose increment every 2-4 weeks</li>
                    <li>Monitor for symptom recurrence</li>
                    <li>Maintain lowest effective dose</li>
                </ul>
            </div>

            <div class="chart-container">
                <canvas id="dosingChart"></canvas>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 9: Missed Dose Management -->
        <div id="section9" class="content-section">
            <h2 class="section-header">‚è∞ 9. MISSED DOSE MANAGEMENT</h2>
            
            <!-- img -->

            <h3>Decision Algorithm</h3>
            <div class="info-box">
                <h4>If Taking ONCE DAILY (180mg):</h4>
                <ul>
                    <li><strong>< 4 hours late:</strong> Take immediately</li>
                    <li><strong>4-8 hours late:</strong> Take if symptom control needed</li>
                    <li><strong>> 8 hours late:</strong> Skip and resume next scheduled dose</li>
                    <li><strong>Never:</strong> Double dose to make up</li>
                </ul>
            </div>

            <div class="success-box">
                <h4>If Taking TWICE DAILY (60mg BID):</h4>
                <ul>
                    <li><strong>Morning dose missed:</strong>
                        <ul>
                            <li>Take if before 2 PM</li>
                            <li>Skip if after 2 PM to avoid evening dose interference</li>
                        </ul>
                    </li>
                    <li><strong>Evening dose missed:</strong>
                        <ul>
                            <li>Take if before bedtime</li>
                            <li>Skip if already sleeping, resume next morning</li>
                        </ul>
                    </li>
                </ul>
            </div>

            <h3>Comprehensive Scenarios</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Scenario</th>
                        <th>Action</th>
                        <th>Reasoning</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Missed 1 dose (once daily)</td>
                        <td>Skip, continue next day</td>
                        <td>Half-life 14 hours provides coverage</td>
                    </tr>
                    <tr>
                        <td>Missed multiple doses</td>
                        <td>Resume regular schedule, don't catch up</td>
                        <td>Avoid excessive dosing</td>
                    </tr>
                    <tr>
                        <td>Unsure if dose taken</td>
                        <td>Skip that dose, resume next scheduled</td>
                        <td>Better to miss than double dose</td>
                    </tr>
                    <tr>
                        <td>Vomited within 30 min of dose</td>
                        <td>Retake dose</td>
                        <td>Likely not absorbed</td>
                    </tr>
                    <tr>
                        <td>Vomited 1+ hour after dose</td>
                        <td>Do not retake</td>
                        <td>Likely absorbed</td>
                    </tr>
                </tbody>
            </table>

            <h3>Recovery Protocol</h3>
            <div class="info-box">
                <p>After missing dose(s):</p>
                <ol>
                    <li>Resume regular dosing schedule</li>
                    <li>Do NOT take extra doses to "catch up"</li>
                    <li>Monitor symptoms - may take 24-48h to regain full control</li>
                    <li>Consider setting medication reminders if frequently forgotten</li>
                </ol>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 10: Drug Conversion -->
        <div id="section10" class="content-section">
            <h2 class="section-header">üîÑ 10. DRUG CONVERSION AND EQUIVALENCY</h2>
            
            <!-- img -->

            <h3>Antihistamine Equivalency Table</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Drug</th>
                        <th>Equivalent Dose</th>
                        <th>Dosing Frequency</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Fexofenadine</strong></td>
                        <td>180mg</td>
                        <td>Once daily</td>
                    </tr>
                    <tr>
                        <td>Loratadine</td>
                        <td>10mg</td>
                        <td>Once daily</td>
                    </tr>
                    <tr>
                        <td>Desloratadine</td>
                        <td>5mg</td>
                        <td>Once daily</td>
                    </tr>
                    <tr>
                        <td>Cetirizine</td>
                        <td>10mg</td>
                        <td>Once daily</td>
                    </tr>
                    <tr>
                        <td>Levocetirizine</td>
                        <td>5mg</td>
                        <td>Once daily</td>
                    </tr>
                </tbody>
            </table>

            <h3>Switching Between Antihistamines</h3>
            <div class="success-box">
                <h4>Cross-Titration Protocol:</h4>
                <p><strong>Direct Switch (No Taper Needed):</strong></p>
                <ul>
                    <li>Stop current antihistamine</li>
                    <li>Start fexofenadine next day at standard dose</li>
                    <li>No washout period required</li>
                    <li>Monitor for symptom control</li>
                </ul>
            </div>

            <h3>Conversion Ratios</h3>
            <div class="info-box">
                <p><strong>Switching TO Fexofenadine:</strong></p>
                <ul>
                    <li>From Loratadine 10mg ‚Üí Fexofenadine 180mg</li>
                    <li>From Cetirizine 10mg ‚Üí Fexofenadine 180mg</li>
                    <li>From Desloratadine 5mg ‚Üí Fexofenadine 180mg</li>
                </ul>
                <p><strong>Switching FROM Fexofenadine:</strong></p>
                <ul>
                    <li>From Fexofenadine 180mg ‚Üí Any equivalent second-gen antihistamine</li>
                </ul>
            </div>

            <h3>Special Considerations</h3>
            <div class="warning-box">
                <h4>‚ö†Ô∏è When Switching:</h4>
                <ul>
                    <li>Consider why previous antihistamine failed</li>
                    <li>Efficacy may vary - trial adequate duration (2-4 weeks)</li>
                    <li>Fexofenadine advantage: No sedation, no drug interactions</li>
                    <li>Remember food/juice interactions unique to fexofenadine</li>
                </ul>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 11: Clinical Efficacy -->
        <div id="section11" class="content-section">
            <h2 class="section-header">üìà 11. CLINICAL EFFICACY DATA</h2>
            
            <!-- img -->

            <h3>Efficacy in Allergic Rhinitis</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Outcome Measure</th>
                        <th>Fexofenadine Result</th>
                        <th>Placebo</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Reduction in total symptom score</td>
                        <td>~45-55%</td>
                        <td>~20-25%</td>
                    </tr>
                    <tr>
                        <td>Sneezing improvement</td>
                        <td>60-70%</td>
                        <td>25-30%</td>
                    </tr>
                    <tr>
                        <td>Rhinorrhea improvement</td>
                        <td>55-65%</td>
                        <td>20-25%</td>
                    </tr>
                    <tr>
                        <td>Nasal itching improvement</td>
                        <td>60-70%</td>
                        <td>25-30%</td>
                    </tr>
                    <tr>
                        <td>Ocular symptoms improvement</td>
                        <td>50-60%</td>
                        <td>20-30%</td>
                    </tr>
                </tbody>
            </table>

            <h3>Efficacy in Chronic Urticaria</h3>
            <div class="success-box">
                <p><strong>Standard Dose (180mg/day):</strong></p>
                <ul>
                    <li>Complete symptom control: 40-50% of patients</li>
                    <li>Partial improvement: Additional 30-40%</li>
                    <li>No response: 10-20%</li>
                </ul>
                <p><strong>High Dose (540mg/day):</strong></p>
                <ul>
                    <li>Complete control: 60-70% of refractory patients</li>
                    <li>Significant improvement in non-responders to standard dose</li>
                </ul>
            </div>

            <h3>Comparative Efficacy Studies</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Comparison</th>
                        <th>Result</th>
                        <th>Clinical Significance</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Fexofenadine vs Loratadine</td>
                        <td>Similar efficacy, faster onset with fexofenadine</td>
                        <td>Both effective choices</td>
                    </tr>
                    <tr>
                        <td>Fexofenadine vs Cetirizine</td>
                        <td>Similar efficacy, less sedation with fexofenadine</td>
                        <td>Fexofenadine preferred for alertness</td>
                    </tr>
                    <tr>
                        <td>Fexofenadine vs Placebo</td>
                        <td>Significantly superior</td>
                        <td>Clear therapeutic benefit</td>
                    </tr>
                </tbody>
            </table>

            <h3>Real-World Effectiveness</h3>
            <div class="info-box">
                <p><strong>Patient Satisfaction Studies:</strong></p>
                <ul>
                    <li>Overall satisfaction: 75-85% of patients</li>
                    <li>Preference over first-generation: 90%+</li>
                    <li>Continuation rate at 1 year: 65-70%</li>
                    <li>Quality of life improvement: Significant in multiple domains</li>
                </ul>
            </div>

            <div class="chart-container">
                <canvas id="efficacyChart"></canvas>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 12: Mechanism of Action -->
        <div id="section12" class="content-section">
            <h2 class="section-header">‚öôÔ∏è 12. MECHANISM OF ACTION</h2>
            
            <!-- img -->

            <h3>Pharmacological Mechanism</h3>
            <div class="success-box">
                <p><strong>Classification:</strong> Selective H1-Receptor Inverse Agonist</p>
                <p><strong>Primary Action:</strong> Stabilizes inactive form of histamine H1 receptor</p>
            </div>

            <h3>Molecular Mechanism</h3>
            <div class="info-box">
                <ol>
                    <li><strong>Receptor Binding:</strong> High-affinity binding to H1 histamine receptors</li>
                    <li><strong>Inverse Agonism:</strong> Actively stabilizes inactive receptor conformation</li>
                    <li><strong>Prevents Activation:</strong> Blocks histamine from binding and activating receptor</li>
                    <li><strong>Downstream Effects:</strong> Inhibits pro-inflammatory cytokine release from mast cells</li>
                </ol>
            </div>

            <h3>Receptor Selectivity Profile</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Receptor Type</th>
                        <th>Affinity</th>
                        <th>Clinical Effect</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>H1 Histamine</strong></td>
                        <td>Very High ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê</td>
                        <td>Potent antihistamine effect</td>
                    </tr>
                    <tr>
                        <td>Muscarinic (Cholinergic)</td>
                        <td>Minimal</td>
                        <td>No anticholinergic effects</td>
                    </tr>
                    <tr>
                        <td>Œ±-Adrenergic</td>
                        <td>Minimal</td>
                        <td>No cardiovascular effects</td>
                    </tr>
                    <tr>
                        <td>CNS Penetration</td>
                        <td>Minimal (P-gp efflux)</td>
                        <td>Non-sedating profile</td>
                    </tr>
                </tbody>
            </table>

            <h3>Physiological Effects Cascade</h3>
            <div class="success-box">
                <h4>Step 1: Allergen Exposure</h4>
                <p>‚Üí Mast cell degranulation</p>
                <p>‚Üí Histamine release</p>
                
                <h4>Step 2: Fexofenadine Action (BLOCKED)</h4>
                <p>‚Üí H1 receptor activation PREVENTED ‚ùå</p>
                <p>‚Üí Pro-inflammatory cascade STOPPED ‚ùå</p>
                
                <h4>Step 3: Clinical Outcomes</h4>
                <ul>
                    <li>‚úÖ Reduced sneezing, rhinorrhea, itching</li>
                    <li>‚úÖ Decreased ocular symptoms</li>
                    <li>‚úÖ Relief of urticaria and pruritus</li>
                    <li>‚úÖ No sedation</li>
                </ul>
            </div>

            <h3>Pharmacokinetics</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Parameter</th>
                        <th>Value</th>
                        <th>Clinical Significance</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Absorption</td>
                        <td>Rapid, 33% bioavailability</td>
                        <td>Food/juice reduce absorption</td>
                    </tr>
                    <tr>
                        <td>Onset</td>
                        <td>1-2 hours</td>
                        <td>Quick relief</td>
                    </tr>
                    <tr>
                        <td>Peak Plasma</td>
                        <td>2-3 hours</td>
                        <td>Maximum effect timing</td>
                    </tr>
                    <tr>
                        <td>Duration</td>
                        <td>12-24 hours</td>
                        <td>Once/twice daily dosing</td>
                    </tr>
                    <tr>
                        <td>Half-Life</td>
                        <td>14.4 hours</td>
                        <td>Supports QD dosing</td>
                    </tr>
                    <tr>
                        <td>Metabolism</td>
                        <td>Minimal (~5%)</td>
                        <td>No significant drug interactions</td>
                    </tr>
                    <tr>
                        <td>Elimination</td>
                        <td>80% feces, 11% urine</td>
                        <td>Renal adjustment needed</td>
                    </tr>
                </tbody>
            </table>

            <div class="chart-container">
                <canvas id="mechanismChart"></canvas>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 13: Contraindications -->
        <div id="section13" class="content-section">
            <h2 class="section-header">üö´ 13. CONTRAINDICATIONS AND PRECAUTIONS</h2>
            
            <!-- img -->

            <h3>Absolute Contraindications</h3>
            <div class="warning-box">
                <h4>‚ùå DO NOT USE IF:</h4>
                <ul>
                    <li><strong>Known hypersensitivity</strong> to fexofenadine or any component</li>
                    <li><strong>Previous serious reaction</strong> (Stevens-Johnson syndrome, anaphylaxis)</li>
                </ul>
            </div>

            <h3>Relative Contraindications</h3>
            <div class="info-box">
                <h4>‚ö†Ô∏è USE WITH CAUTION:</h4>
                <ul>
                    <li>Severe renal impairment (CrCl < 10 mL/min)</li>
                    <li>Concurrent P-glycoprotein inhibitors</li>
                    <li>Infants under 6 months</li>
                    <li>Cardiovascular disease with QT prolongation history</li>
                </ul>
            </div>

            <h3>Drug-Disease Contraindications</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Disease State</th>
                        <th>Concern</th>
                        <th>Recommendation</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>End-Stage Renal Disease</td>
                        <td>Drug accumulation</td>
                        <td>Reduce dose to 60mg QD, monitor closely</td>
                    </tr>
                    <tr>
                        <td>Severe Hepatic Impairment</td>
                        <td>Minimal concern (not metabolized)</td>
                        <td>No adjustment typically needed</td>
                    </tr>
                    <tr>
                        <td>Long QT Syndrome</td>
                        <td>Theoretical arrhythmia risk</td>
                        <td>Monitor ECG, use alternative if possible</td>
                    </tr>
                    <tr>
                        <td>Phenylketonuria (PKU)</td>
                        <td>ODT contains phenylalanine</td>
                        <td>Avoid ODT form, use regular tablets</td>
                    </tr>
                </tbody>
            </table>

            <h3>Special Precautions</h3>
            <div class="success-box">
                <h4>Pregnancy & Lactation:</h4>
                <ul>
                    <li>Category C - use only if benefit outweighs risk</li>
                    <li>Limited human data available</li>
                    <li>Excreted in breast milk in small amounts</li>
                </ul>
                
                <h4>Elderly:</h4>
                <ul>
                    <li>Increased risk of renal impairment - check function</li>
                    <li>May start with lower dose</li>
                    <li>Monitor for unusual effects</li>
                </ul>
                
                <h4>Pediatrics:</h4>
                <ul>
                    <li>Not approved under 6 months</li>
                    <li>Use age-appropriate formulation and dosing</li>
                </ul>
            </div>

            <h3>Risk-Benefit Assessment</h3>
            <div class="info-box">
                <p><strong>When to Use Despite Cautions:</strong></p>
                <ul>
                    <li>Severe allergic symptoms impacting quality of life</li>
                    <li>Other antihistamines failed or contraindicated</li>
                    <li>Benefits of symptom control outweigh theoretical risks</li>
                    <li>Close monitoring can be ensured</li>
                </ul>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 14: Drug Interactions -->
        <div id="section14" class="content-section">
            <h2 class="section-header">üîÑ 14. COMPREHENSIVE INTERACTION ANALYSIS</h2>
            
            <!-- img -->

            <h3>Major Drug-Drug Interactions</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Interacting Drug</th>
                        <th>Mechanism</th>
                        <th>Effect</th>
                        <th>Management</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Ketoconazole</td>
                        <td>P-gp inhibition</td>
                        <td>‚Üë Fexofenadine 135%</td>
                        <td>Monitor, reduce dose if needed</td>
                    </tr>
                    <tr>
                        <td>Erythromycin</td>
                        <td>P-gp inhibition</td>
                        <td>‚Üë Fexofenadine 109%</td>
                        <td>Usually tolerated, monitor</td>
                    </tr>
                    <tr>
                        <td>Rifampin</td>
                        <td>P-gp induction</td>
                        <td>‚Üì Fexofenadine 83%</td>
                        <td>May need dose increase</td>
                    </tr>
                    <tr>
                        <td>Verapamil</td>
                        <td>P-gp inhibition</td>
                        <td>‚Üë Absorption</td>
                        <td>Monitor effects</td>
                    </tr>
                    <tr>
                        <td>Antacids (Al/Mg)</td>
                        <td>Chelation</td>
                        <td>‚Üì Absorption 40%</td>
                        <td>Separate by 2 hours</td>
                    </tr>
                </tbody>
            </table>

            <h3>Critical Drug-Food Interactions</h3>
            <div class="warning-box">
                <h4>‚ö†Ô∏è CRITICAL: Avoid These Beverages</h4>
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Food/Beverage</th>
                            <th>Impact</th>
                            <th>Mechanism</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>üçé Apple Juice</td>
                            <td>‚Üì 71% absorption</td>
                            <td>OATP1A2 inhibition</td>
                        </tr>
                        <tr>
                            <td>üçä Orange Juice</td>
                            <td>‚Üì 68% absorption</td>
                            <td>OATP1A2 inhibition</td>
                        </tr>
                        <tr>
                            <td>üçá Grapefruit Juice</td>
                            <td>‚Üì 42% absorption</td>
                            <td>OATP inhibition</td>
                        </tr>
                        <tr>
                            <td>üçî High-Fat Meals</td>
                            <td>‚Üì 21% bioavailability</td>
                            <td>Delayed gastric emptying</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <h3>Drug-Laboratory Test Interactions</h3>
            <div class="info-box">
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Test</th>
                            <th>Effect</th>
                            <th>Recommendation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>Allergy Skin Testing</td>
                            <td>False-negative results</td>
                            <td>Discontinue 3-7 days before</td>
                        </tr>
                        <tr>
                            <td>Wheal & Flare Response</td>
                            <td>Suppressed reaction</td>
                            <td>Stop 72 hours before</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <h3>Moderate Interactions</h3>
            <ul>
                <li><strong>CNS Depressants:</strong> No additive sedation (unlike first-gen)</li>
                <li><strong>Alcohol:</strong> No significant interaction</li>
                <li><strong>QT-Prolonging Drugs:</strong> Use caution in combination</li>
            </ul>

            <div class="chart-container">
                <canvas id="interactionsChart"></canvas>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 15: Adverse Effects -->
        <div id="section15" class="content-section">
            <h2 class="section-header">‚ö° 15. COMPLETE ADVERSE REACTION PROFILE</h2>
            
            <!-- img -->

            <h3>Side Effects by Frequency</h3>
            
            <h4>Common (>1% - 10%)</h4>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Side Effect</th>
                        <th>Frequency</th>
                        <th>Management</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Headache</td>
                        <td>10.6%</td>
                        <td>Usually mild, self-limiting</td>
                    </tr>
                    <tr>
                        <td>Drowsiness</td>
                        <td>1.3%</td>
                        <td>Take at bedtime if bothersome</td>
                    </tr>
                    <tr>
                        <td>Dizziness</td>
                        <td>1.5%</td>
                        <td>Avoid sudden position changes</td>
                    </tr>
                    <tr>
                        <td>Nausea</td>
                        <td>1.6%</td>
                        <td>Take with small amount of food</td>
                    </tr>
                    <tr>
                        <td>Dyspepsia</td>
                        <td>1.3%</td>
                        <td>Antacids (separate by 2h)</td>
                    </tr>
                </tbody>
            </table>

            <h4>Uncommon (0.1% - 1%)</h4>
            <ul>
                <li>Dry mouth</li>
                <li>Back pain</li>
                <li>Abdominal pain</li>
                <li>Diarrhea</li>
                <li>Muscle pain</li>
                <li>Upper respiratory infection</li>
            </ul>

            <h4>Rare (0.01% - 0.1%)</h4>
            <ul>
                <li>Tachycardia</li>
                <li>Palpitations</li>
                <li>Insomnia</li>
                <li>Nervousness</li>
                <li>Rash</li>
            </ul>

            <h4>Very Rare (<0.01%)</h4>
            <div class="warning-box">
                <h4>üö® Serious Reactions:</h4>
                <ul>
                    <li><strong>Stevens-Johnson Syndrome</strong></li>
                    <li><strong>Anaphylaxis/Angioedema</strong></li>
                    <li>Hypersensitivity reactions</li>
                    <li>Leukopenia</li>
                </ul>
            </div>

            <div class="chart-container">
                <canvas id="sideEffectsChart"></canvas>
            </div>

            <h3>Management Protocols</h3>
            <div class="success-box">
                <h4>‚úÖ Mild Effects:</h4>
                <p>Continue medication, symptoms often resolve</p>
                
                <h4>‚ö†Ô∏è Moderate Effects:</h4>
                <p>Consider dose reduction or alternative antihistamine</p>
                
                <h4>üö® Severe Effects:</h4>
                <p>DISCONTINUE IMMEDIATELY, seek medical attention</p>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 16: Patient-Reported Concerns -->
        <div id="section16" class="content-section">
            <h2 class="section-header">üë• 16. PUBLIC CONCERNS AND SOCIAL MEDIA REPORTS</h2>
            
            <!-- img -->

            <h3>Widely Discussed Effects (Social Media & Forums)</h3>
            <div class="info-box">
                <p><strong>Note:</strong> Patient-reported from online forums, Reddit, Facebook. Clinical validation varies.</p>
            </div>

            <h4>Reproductive & Fertility Concerns</h4>
            <ul>
                <li><strong>"Does it affect fertility?"</strong> - Common question, NO clinical evidence</li>
                <li><strong>"Safe while trying to conceive?"</strong> - Generally considered safe</li>
                <li><strong>"Impact on libido?"</strong> - Very rare reports, not established</li>
            </ul>

            <h4>Weight & Metabolism</h4>
            <ul>
                <li><strong>"Weight gain"</strong> - Occasionally reported, not confirmed in trials</li>
                <li><strong>"Increased appetite"</strong> - Rare mentions, mechanism unclear</li>
            </ul>

            <h4>Mental Health</h4>
            <ul>
                <li><strong>"Brain fog"</strong> - Some reports despite non-sedating profile</li>
                <li><strong>"Mood changes"</strong> - Minimal evidence</li>
                <li><strong>"Anxiety"</strong> - Rare reports, not established causation</li>
            </ul>

            <h4>Cosmetic & Physical Changes</h4>
            <ul>
                <li><strong>"Hair loss/thinning"</strong> - Very rare reports, not confirmed</li>
                <li><strong>"Dry skin"</strong> - Occasionally mentioned</li>
                <li><strong>"Acne changes"</strong> - Not documented in clinical literature</li>
            </ul>

            <h3>Effects NOT in Official Prescribing Information</h3>
            <div class="warning-box">
                <h4>‚ö†Ô∏è Unverified Patient Reports:</h4>
                <p>These effects are discussed online but lack clinical validation:</p>
                <ul>
                    <li>Vivid dreams</li>
                    <li>Muscle twitching</li>
                    <li>Tingling sensations</li>
                    <li>Changes in taste perception</li>
                </ul>
                <p><strong>Important:</strong> If experiencing unusual symptoms, consult healthcare provider.</p>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 17: Case Reports -->
        <div id="section17" class="content-section">
            <h2 class="section-header">üìã 17. CASE REPORTS AND MEDIA COVERAGE</h2>
            
            <!-- img -->

            <h3>Updated Case Reports (2024-2025)</h3>
            <div class="success-box">
                <p><strong>25-Year Safety Review:</strong></p>
                <p>Published in 2024, comprehensive analysis of fexofenadine clinical experience shows:</p>
                <ul>
                    <li>Excellent safety profile maintained over 25+ years</li>
                    <li>Minimal serious adverse events reported</li>
                    <li>Truly non-sedating confirmed in real-world use</li>
                    <li>No cardiac toxicity cases (unlike parent compound)</li>
                </ul>
            </div>

            <h3>Notable Case Reports</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Case Type</th>
                        <th>Findings</th>
                        <th>Outcome</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>High-Dose Chronic Urticaria</td>
                        <td>Up to 540mg/day well-tolerated</td>
                        <td>Effective for refractory cases</td>
                    </tr>
                    <tr>
                        <td>Pediatric Long-Term Use</td>
                        <td>Safe for continuous use >5 years</td>
                        <td>No growth/development impact</td>
                    </tr>
                    <tr>
                        <td>Elderly Population</td>
                        <td>Safe in patients >80 years</td>
                        <td>Dose adjustment per renal function</td>
                    </tr>
                    <tr>
                        <td>Pregnancy Registries</td>
                        <td>No increased malformation risk</td>
                        <td>Reassuring safety data</td>
                    </tr>
                </tbody>
            </table>

            <h3>Media Coverage Highlights</h3>
            <div class="info-box">
                <ul>
                    <li><strong>2024:</strong> Major medical journals celebrate 25-year milestone</li>
                    <li><strong>Consumer Reports:</strong> Rated highly for allergy relief with minimal side effects</li>
                    <li><strong>Medical News:</strong> High-dose protocols gaining recognition</li>
                    <li><strong>Patient Advocacy:</strong> Recommended by allergy patient organizations</li>
                </ul>
            </div>

            <h3>Controversial Reports Evaluation</h3>
            <div class="warning-box">
                <h4>Addressing Concerns:</h4>
                <p><strong>Claim:</strong> "Antihistamines cause dementia"</p>
                <p><strong>Evaluation:</strong> Studies refer to FIRST-GENERATION anticholinergic antihistamines, NOT fexofenadine which has no anticholinergic activity.</p>
                
                <p><strong>Claim:</strong> "Heart problems like terfenadine"</p>
                <p><strong>Evaluation:</strong> Fexofenadine is the SAFE metabolite of terfenadine, without cardiac toxicity. 25+ years with no cardiac cases.</p>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 18: Pregnancy & Preconception -->
        <div id="section18" class="content-section">
            <h2 class="section-header">ü§∞ 18. PREGNANCY AND PRECONCEPTION</h2>
            
            <!-- img -->

            <h3>Preconception Use</h3>
            <div class="success-box">
                <p><strong>Risk Assessment:</strong> Low risk, no fertility impact evidence</p>
                <p><strong>Recommendation:</strong> Can continue if needed for symptom control</p>
                <p><strong>Timing:</strong> No need to discontinue when attempting conception</p>
            </div>

            <h3>Use During Pregnancy</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Trimester</th>
                        <th>Risk Assessment</th>
                        <th>Recommendation</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>First Trimester</td>
                        <td>Theoretical risk, limited data</td>
                        <td>Use only if clearly needed</td>
                    </tr>
                    <tr>
                        <td>Second Trimester</td>
                        <td>No increased risk observed</td>
                        <td>Acceptable if benefit outweighs risk</td>
                    </tr>
                    <tr>
                        <td>Third Trimester</td>
                        <td>No adverse effects reported</td>
                        <td>Can use if needed</td>
                    </tr>
                </tbody>
            </table>

            <h3>Teratogenic Potential</h3>
            <div class="info-box">
                <p><strong>Animal Studies:</strong> No teratogenic effects at 300x human dose</p>
                <p><strong>Human Data:</strong> Limited controlled studies, observational data reassuring</p>
                <p><strong>Birth Defects:</strong> No increased risk identified</p>
            </div>

            <h3>Pregnancy Risk Category</h3>
            <div class="success-box">
                <p><strong>FDA Category:</strong> C (historical)</p>
                <p><strong>Meaning:</strong> Insufficient human data, NOT proven harm</p>
                <p><strong>Current Assessment:</strong> Use when benefit exceeds theoretical risk</p>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 19: Lactation -->
        <div id="section19" class="content-section">
            <h2 class="section-header">ü§± 19. LACTATION AND BREASTFEEDING</h2>
            
            <!-- img -->

            <h3>Breast Milk Excretion</h3>
            <div class="success-box">
                <p><strong>Excretion:</strong> Yes, in small amounts</p>
                <p><strong>Infant Exposure:</strong> ~0.45% of maternal weight-adjusted dose</p>
                <p><strong>Infant Risk:</strong> Likely minimal to none</p>
            </div>

            <h3>Breastfeeding Recommendations</h3>
            <div class="info-box">
                <ul>
                    <li><strong>‚úÖ Generally Compatible:</strong> AAP considers acceptable</li>
                    <li><strong>Preferred Timing:</strong> Take immediately after nursing</li>
                    <li><strong>Monitoring:</strong> Watch for drowsiness or irritability in infant (rare)</li>
                    <li><strong>Alternatives:</strong> Loratadine or cetirizine may be preferred (more data)</li>
                </ul>
            </div>

            <h3>LactMed Risk Category</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Parameter</th>
                        <th>Assessment</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Category</td>
                        <td>Probably Compatible</td>
                    </tr>
                    <tr>
                        <td>Evidence Level</td>
                        <td>Limited human data, theoretical low risk</td>
                    </tr>
                    <tr>
                        <td>Alternative Preference</td>
                        <td>Other second-gen antihistamines may be preferred</td>
                    </tr>
                </tbody>
            </table>

            <h3>Infant Monitoring</h3>
            <div class="warning-box">
                <h4>‚ö†Ô∏è Monitor Infant For:</h4>
                <ul>
                    <li>Unusual drowsiness or lethargy</li>
                    <li>Irritability or restlessness</li>
                    <li>Poor feeding</li>
                    <li>Any unexpected symptoms</li>
                </ul>
                <p><strong>Note:</strong> These effects are RARE but should prompt consultation.</p>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 20: Safety Monitoring -->
        <div id="section20" class="content-section">
            <h2 class="section-header">üìä 20. SAFETY MONITORING REQUIREMENTS</h2>
            
            <!-- img -->

            <h3>Required Monitoring Parameters</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Parameter</th>
                        <th>Frequency</th>
                        <th>Indication</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Renal Function</td>
                        <td>Baseline, annually</td>
                        <td>Dose adjustment in impairment</td>
                    </tr>
                    <tr>
                        <td>Clinical Response</td>
                        <td>Every 2-4 weeks initially</td>
                        <td>Assess efficacy</td>
                    </tr>
                    <tr>
                        <td>Adverse Effects</td>
                        <td>Ongoing</td>
                        <td>Patient reporting</td>
                    </tr>
                    <tr>
                        <td>ECG (if indicated)</td>
                        <td>Baseline if risk factors</td>
                        <td>Cardiac history patients</td>
                    </tr>
                </tbody>
            </table>

            <h3>Laboratory Monitoring</h3>
            <div class="success-box">
                <h4>Standard Monitoring:</h4>
                <ul>
                    <li><strong>NO routine lab monitoring required</strong> for most patients</li>
                    <li>Minimal hepatic metabolism = no liver function tests</li>
                    <li>Renal elimination = monitor kidney function in elderly/impaired</li>
                </ul>
            </div>

            <h3>Clinical Assessment Schedule</h3>
            <div class="info-box">
                <h4>Initial Phase (First 3 Months):</h4>
                <ul>
                    <li>Week 2: Assess initial response</li>
                    <li>Week 4: Evaluate efficacy and tolerability</li>
                    <li>Month 3: Determine need for continued therapy</li>
                </ul>
                
                <h4>Maintenance Phase:</h4>
                <ul>
                    <li>Every 6 months: Clinical assessment</li>
                    <li>Annually: Renal function check (elderly)</li>
                    <li>As needed: Reassess if changes occur</li>
                </ul>
            </div>

            <h3>Alert Thresholds</h3>
            <div class="warning-box">
                <h4>üö® Contact Healthcare Provider If:</h4>
                <ul>
                    <li>Severe rash or skin reaction develops</li>
                    <li>Difficulty breathing or swallowing</li>
                    <li>Rapid or irregular heartbeat</li>
                    <li>Severe dizziness or fainting</li>
                    <li>Unusual bleeding or bruising</li>
                </ul>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 21: Storage & Handling -->
        <div id="section21" class="content-section">
            <h2 class="section-header">üè• 21. STORAGE AND HANDLING</h2>
            
            <!-- img -->

            <h3>Storage Requirements by Formulation</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Formulation</th>
                        <th>Storage Conditions</th>
                        <th>Stability</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Tablets</td>
                        <td>20-25¬∞C (68-77¬∞F), protect from moisture</td>
                        <td>Until expiration date</td>
                    </tr>
                    <tr>
                        <td>ODT</td>
                        <td>20-25¬∞C, keep in original blister</td>
                        <td>Moisture-sensitive</td>
                    </tr>
                    <tr>
                        <td>Oral Suspension</td>
                        <td>Refrigerate 2-8¬∞C after opening</td>
                        <td>90 days after opening</td>
                    </tr>
                </tbody>
            </table>

            <h3>Handling Precautions</h3>
            <div class="info-box">
                <ul>
                    <li><strong>Tablets:</strong> Keep in original container with desiccant</li>
                    <li><strong>ODT:</strong> Do not remove from blister until ready to use</li>
                    <li><strong>Suspension:</strong> Shake well before each use</li>
                    <li><strong>All Forms:</strong> Keep out of reach of children</li>
                </ul>
            </div>

            <h3>Class-Specific Differences</h3>
            <div class="success-box">
                <p><strong>Fexofenadine vs Other Antihistamines:</strong></p>
                <ul>
                    <li>More sensitive to moisture than loratadine</li>
                    <li>Suspension requires refrigeration (unlike cetirizine)</li>
                    <li>ODT form particularly moisture-sensitive</li>
                </ul>
            </div>

            <h3>Travel Considerations</h3>
            <div class="info-box">
                <ul>
                    <li>Store in original container with prescription label</li>
                    <li>Protect from extreme heat (avoid car dashboard)</li>
                    <li>Suspension may need cooler with ice packs</li>
                    <li>Consider tablets for extended travel (more stable)</li>
                </ul>
            </div>

            <h3>Disposal Guidelines</h3>
            <div class="warning-box">
                <h4>‚ö†Ô∏è Proper Disposal:</h4>
                <ul>
                    <li>Do NOT flush down toilet</li>
                    <li>Use drug take-back programs (preferred)</li>
                    <li>If unavailable: Mix with unpalatable substance (coffee grounds), seal in bag, dispose in household trash</li>
                    <li>Remove all personal information from prescription label</li>
                </ul>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 22: Prolonged Use Effects -->
        <div id="section22" class="content-section">
            <h2 class="section-header">‚è≥ 22. PROLONGED USE EFFECTS</h2>
            
            <!-- img -->

            <h3>Long-Term Safety Profile</h3>
            <div class="success-box">
                <h4>‚úÖ Excellent Long-Term Safety:</h4>
                <ul>
                    <li><strong>25+ years</strong> of clinical experience</li>
                    <li><strong>No tolerance development</strong> - maintains efficacy</li>
                    <li><strong>No withdrawal symptoms</strong> upon discontinuation</li>
                    <li><strong>No organ toxicity</strong> with chronic use</li>
                </ul>
            </div>

            <h3>Long-Term Side Effect Profile</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>System</th>
                        <th>Long-Term Findings</th>
                        <th>Clinical Significance</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Cardiovascular</td>
                        <td>No cardiac toxicity</td>
                        <td>Safe for prolonged use</td>
                    </tr>
                    <tr>
                        <td>Hepatic</td>
                        <td>No liver enzyme elevation</td>
                        <td>No monitoring needed</td>
                    </tr>
                    <tr>
                        <td>Renal</td>
                        <td>No nephrotoxicity</td>
                        <td>Safe with normal function</td>
                    </tr>
                    <tr>
                        <td>Central Nervous System</td>
                        <td>No cognitive impairment</td>
                        <td>No dementia risk</td>
                    </tr>
                    <tr>
                        <td>Immune System</td>
                        <td>No immunosuppression</td>
                        <td>Normal immune function</td>
                    </tr>
                </tbody>
            </table>

            <h3>Class-Specific Considerations</h3>
            <div class="info-box">
                <p><strong>Fexofenadine vs First-Generation Antihistamines:</strong></p>
                <ul>
                    <li>No anticholinergic effects (no dementia risk)</li>
                    <li>No tolerance or tachyphylaxis</li>
                    <li>Maintains non-sedating profile long-term</li>
                    <li>Safe for chronic use in all age groups</li>
                </ul>
            </div>

            <h3>Tolerance Development Patterns</h3>
            <div class="success-box">
                <p><strong>Good News:</strong></p>
                <ul>
                    <li><strong>NO tolerance development</strong> to therapeutic effects</li>
                    <li>Efficacy maintained over years of continuous use</li>
                    <li>No need for dose escalation due to tolerance</li>
                    <li>Sustained symptom control achievable</li>
                </ul>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 23: Nutritional Support -->
        <div id="section23" class="content-section">
            <h2 class="section-header">ü•ó 23. NUTRITIONAL SUPPORT & DIETARY CONSIDERATIONS</h2>
            
            <!-- img -->

            <h3>Dietary Restrictions</h3>
            <div class="warning-box">
                <h4>‚ö†Ô∏è AVOID These Foods/Drinks:</h4>
                <ul>
                    <li><strong>Apple Juice:</strong> Blocks absorption by 71%</li>
                    <li><strong>Orange Juice:</strong> Blocks absorption by 68%</li>
                    <li><strong>Grapefruit Juice:</strong> Blocks absorption by 42%</li>
                    <li><strong>High-Fat Meals:</strong> Reduces absorption by 21%</li>
                </ul>
                <p><strong>Timing:</strong> Avoid these for 2 hours before and after dose</p>
            </div>

            <h3>Optimal Nutrition Timing</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Timing</th>
                        <th>Recommendation</th>
                        <th>Rationale</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Best Time to Take</strong></td>
                        <td>On empty stomach with water</td>
                        <td>Maximizes bioavailability</td>
                    </tr>
                    <tr>
                        <td><strong>Morning Option</strong></td>
                        <td>30-60 min before breakfast</td>
                        <td>Allows absorption before food</td>
                    </tr>
                    <tr>
                        <td><strong>Evening Option</strong></td>
                        <td>2+ hours after dinner</td>
                        <td>Stomach is clear</td>
                    </tr>
                    <tr>
                        <td><strong>With Food</strong></td>
                        <td>OK if GI upset occurs (rare)</td>
                        <td>Slight reduction in absorption acceptable</td>
                    </tr>
                </tbody>
            </table>

            <h3>Nutritional Interactions</h3>
            <div class="success-box">
                <h4>‚úÖ Safe to Consume:</h4>
                <ul>
                    <li>Water (best choice)</li>
                    <li>Coffee or tea (without milk close to dose time)</li>
                    <li>Most solid foods (after 30-60 min wait)</li>
                    <li>Vegetables and fruits (not as juice)</li>
                    <li>Protein-rich foods</li>
                </ul>
            </div>

            <h3>Supplements & Vitamins</h3>
            <div class="info-box">
                <p><strong>Generally Compatible:</strong></p>
                <ul>
                    <li>Multivitamins: No interaction</li>
                    <li>Vitamin C: Safe (but not as orange juice!)</li>
                    <li>Vitamin D: No interaction</li>
                    <li>Omega-3: No interaction</li>
                    <li>Probiotics: No interaction</li>
                </ul>
                <p><strong>Caution:</strong></p>
                <ul>
                    <li><strong>Antacids (Al/Mg):</strong> Separate by 2 hours</li>
                    <li><strong>St. John's Wort:</strong> May reduce fexofenadine levels - AVOID</li>
                </ul>
            </div>

            <h3>Allergy-Friendly Diet Support</h3>
            <div class="success-box">
                <h4>Foods That May Help with Allergies:</h4>
                <ul>
                    <li><strong>Quercetin-rich:</strong> Apples (eaten whole, not juice!), onions, berries</li>
                    <li><strong>Omega-3 fatty acids:</strong> Fish, flaxseed, walnuts</li>
                    <li><strong>Probiotics:</strong> Yogurt, kefir, fermented foods</li>
                    <li><strong>Vitamin C:</strong> Bell peppers, broccoli, citrus (eaten whole)</li>
                </ul>
                <p><em>Note: These are complementary; do not replace medication</em></p>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 24: Side Effect Management -->
        <div id="section24" class="content-section">
            <h2 class="section-header">ü©∫ 24. SIDE EFFECT MANAGEMENT STRATEGIES</h2>
            
            <!-- img -->

            <h3>Management by Side Effect</h3>
            
            <div class="info-box">
                <h4>Headache (10.6% incidence)</h4>
                <p><strong>Management:</strong></p>
                <ul>
                    <li>Usually mild and transient (resolves in 1-2 weeks)</li>
                    <li>Take with food if related to empty stomach</li>
                    <li>OTC acetaminophen safe to use concurrently</li>
                    <li>Ensure adequate hydration</li>
                    <li>If severe or persistent, consider dose reduction</li>
                </ul>
            </div>

            <div class="info-box">
                <h4>Nausea/Dyspepsia (1-2% incidence)</h4>
                <p><strong>Management:</strong></p>
                <ul>
                    <li>Take with small amount of food (despite absorption reduction)</li>
                    <li>Avoid spicy or fatty foods around dose time</li>
                    <li>Ginger supplements may help</li>
                    <li>Usually resolves with continued use</li>
                </ul>
            </div>

            <div class="info-box">
                <h4>Dizziness (1.5% incidence)</h4>
                <p><strong>Management:</strong></p>
                <ul>
                    <li>Stand up slowly from sitting/lying position</li>
                    <li>Ensure adequate hydration</li>
                    <li>Avoid driving until effect subsides</li>
                    <li>Consider taking at bedtime instead</li>
                    <li>If persistent, evaluate for other causes</li>
                </ul>
            </div>

            <div class="info-box">
                <h4>Drowsiness (0.8% incidence - rare)</h4>
                <p><strong>Management:</strong></p>
                <ul>
                    <li>Take at bedtime</li>
                    <li>Avoid alcohol and other CNS depressants</li>
                    <li>Reassess if truly due to fexofenadine (very unusual)</li>
                    <li>Consider switching to different time of day</li>
                </ul>
            </div>

            <h3>When to Contact Healthcare Provider</h3>
            <div class="warning-box">
                <h4>üö® Contact Doctor If:</h4>
                <ul>
                    <li>Side effects are severe or worsening</li>
                    <li>New symptoms develop after starting medication</li>
                    <li>Rash, hives, or swelling (possible allergy)</li>
                    <li>Chest pain, palpitations, or irregular heartbeat</li>
                    <li>Severe dizziness or fainting</li>
                    <li>Persistent nausea/vomiting</li>
                </ul>
            </div>

            <h3>Dose Modification Strategies</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Scenario</th>
                        <th>Current Dose</th>
                        <th>Modification</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Intolerable side effects</td>
                        <td>180mg QD</td>
                        <td>Try 60mg BID or 60mg QD</td>
                    </tr>
                    <tr>
                        <td>Mild side effects</td>
                        <td>60mg BID</td>
                        <td>Take both doses with food</td>
                    </tr>
                    <tr>
                        <td>Timing-related effects</td>
                        <td>Morning dose</td>
                        <td>Switch to bedtime dosing</td>
                    </tr>
                </tbody>
            </table>

            <h3>Alternative Strategies</h3>
            <div class="success-box">
                <p>If side effects persist despite management:</p>
                <ul>
                    <li>Switch to alternative second-generation antihistamine (loratadine, cetirizine)</li>
                    <li>Consider combination with nasal steroid (allows lower antihistamine dose)</li>
                    <li>Evaluate for non-pharmacological interventions</li>
                </ul>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 25: Dermatological Issues -->
        <div id="section25" class="content-section">
            <h2 class="section-header">ü©π 25. DERMATOLOGICAL CONSIDERATIONS</h2>
            
            <!-- img -->

            <h3>Skin Conditions Treated</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Condition</th>
                        <th>Efficacy</th>
                        <th>Typical Response Time</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Chronic Urticaria</strong></td>
                        <td>Excellent (FDA-approved)</td>
                        <td>1-7 days</td>
                    </tr>
                    <tr>
                        <td>Physical Urticarias</td>
                        <td>Good</td>
                        <td>3-14 days</td>
                    </tr>
                    <tr>
                        <td>Dermographism</td>
                        <td>Good</td>
                        <td>1-3 days</td>
                    </tr>
                    <tr>
                        <td>Cholinergic Urticaria</td>
                        <td>Moderate</td>
                        <td>1-2 weeks</td>
                    </tr>
                    <tr>
                        <td>Cold Urticaria</td>
                        <td>Moderate-Good</td>
                        <td>1 week</td>
                    </tr>
                    <tr>
                        <td>Allergic Contact Dermatitis</td>
                        <td>Adjunctive only</td>
                        <td>Variable</td>
                    </tr>
                </tbody>
            </table>

            <h3>Skin-Related Adverse Effects</h3>
            <div class="warning-box">
                <h4>Rare but Serious:</h4>
                <ul>
                    <li><strong>Angioedema:</strong> <0.1% incidence - discontinue immediately</li>
                    <li><strong>Urticaria (paradoxical):</strong> Extremely rare - consider drug allergy</li>
                    <li><strong>Rash:</strong> <1% - usually mild, self-limiting</li>
                    <li><strong>Pruritus without rash:</strong> Very rare - investigate other causes</li>
                </ul>
            </div>

            <h3>Photosensitivity</h3>
            <div class="success-box">
                <p><strong>Good News:</strong> Fexofenadine does NOT cause photosensitivity</p>
                <ul>
                    <li>Safe sun exposure while taking medication</li>
                    <li>No increased sunburn risk</li>
                    <li>Still use appropriate sun protection as normally recommended</li>
                </ul>
            </div>

            <h3>Management of Urticaria</h3>
            <div class="info-box">
                <h4>Step-Up Approach for Chronic Urticaria:</h4>
                <ol>
                    <li><strong>Step 1:</strong> Fexofenadine 180mg once daily</li>
                    <li><strong>Step 2:</strong> Increase to 180mg BID (360mg/day) if inadequate response after 2 weeks</li>
                    <li><strong>Step 3:</strong> Increase to 180mg TID (540mg/day) for refractory cases</li>
                    <li><strong>Step 4:</strong> Add omalizumab or other immunomodulator if still uncontrolled</li>
                </ol>
            </div>

            <h3>Combination Dermatological Therapy</h3>
            <div class="success-box">
                <p><strong>Often combined with:</strong></p>
                <ul>
                    <li><strong>H2-blockers:</strong> (e.g., famotidine) for synergistic effect in urticaria</li>
                    <li><strong>Leukotriene inhibitors:</strong> (e.g., montelukast) for resistant cases</li>
                    <li><strong>Topical corticosteroids:</strong> For localized lesions</li>
                    <li><strong>Moisturizers:</strong> For associated dry skin</li>
                </ul>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 26: Special Populations -->
        <div id="section26" class="content-section">
            <h2 class="section-header">üë®‚Äçüë©‚Äçüëß‚Äçüë¶ 26. SPECIAL POPULATIONS</h2>
            
            <!-- img -->

            <h3>Pediatric Population</h3>
            <div class="info-box">
                <h4>Age-Specific Dosing:</h4>
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Age Group</th>
                            <th>Dose</th>
                            <th>Special Considerations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>6 months - 2 years</td>
                            <td>15mg (2.5mL) BID</td>
                            <td>Use oral suspension only</td>
                        </tr>
                        <tr>
                            <td>2-11 years</td>
                            <td>30mg BID</td>
                            <td>Tablets or suspension</td>
                        </tr>
                        <tr>
                            <td>‚â•12 years</td>
                            <td>Adult dosing</td>
                            <td>Same as adults</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <h3>Geriatric Population (‚â•65 years)</h3>
            <div class="success-box">
                <p><strong>Safety Profile:</strong> Excellent in elderly</p>
                <ul>
                    <li><strong>Dosing:</strong> Same as younger adults in most cases</li>
                    <li><strong>Advantages:</strong> No sedation, no anticholinergic effects</li>
                    <li><strong>Consideration:</strong> Check renal function, adjust if CrCl <60</li>
                    <li><strong>Drug Interactions:</strong> Lower risk due to minimal metabolism</li>
                </ul>
            </div>

            <h3>Renal Impairment</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>CrCl (mL/min)</th>
                        <th>Recommended Dose</th>
                        <th>Rationale</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>>80</td>
                        <td>180mg QD or 60mg BID</td>
                        <td>Normal dosing</td>
                    </tr>
                    <tr>
                        <td>50-80</td>
                        <td>No adjustment</td>
                        <td>Adequate clearance</td>
                    </tr>
                    <tr>
                        <td>30-50</td>
                        <td>60mg QD</td>
                        <td>Reduced clearance</td>
                    </tr>
                    <tr>
                        <td><30</td>
                        <td>60mg QD, monitor</td>
                        <td>Significantly reduced clearance</td>
                    </tr>
                    <tr>
                        <td>Hemodialysis</td>
                        <td>60mg QD (not dialyzable)</td>
                        <td>Not removed by dialysis</td>
                    </tr>
                </tbody>
            </table>

            <h3>Hepatic Impairment</h3>
            <div class="success-box">
                <p><strong>Good News:</strong> No dose adjustment needed!</p>
                <ul>
                    <li>Minimal hepatic metabolism (<5%)</li>
                    <li>Safe in cirrhosis and liver disease</li>
                    <li>No accumulation in hepatic failure</li>
                </ul>
            </div>

            <h3>Athletes & Performance</h3>
            <div class="info-box">
                <p><strong>Athletic Considerations:</strong></p>
                <ul>
                    <li><strong>WADA Status:</strong> NOT prohibited - legal for competitive athletes</li>
                    <li><strong>Performance:</strong> No impairment of reaction time or coordination</li>
                    <li><strong>Exercise-Induced Urticaria:</strong> May be beneficial</li>
                    <li><strong>Sweating:</strong> Does not affect thermoregulation</li>
                </ul>
            </div>

            <h3>Occupational Considerations</h3>
            <div class="success-box">
                <h4>Safe for:</h4>
                <ul>
                    <li>Pilots and air traffic controllers</li>
                    <li>Commercial drivers</li>
                    <li>Machine operators</li>
                    <li>Healthcare professionals</li>
                    <li>Military personnel</li>
                </ul>
                <p><em>No impairment of alertness or psychomotor performance</em></p>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 27: Laboratory Profile -->
        <div id="section27" class="content-section">
            <h2 class="section-header">üß™ 27. LABORATORY TEST INTERACTIONS</h2>
            
            <!-- img -->

            <h3>Allergy Testing Interference</h3>
            <div class="warning-box">
                <h4>‚ö†Ô∏è IMPORTANT: Must Discontinue Before Allergy Testing</h4>
                <p><strong>Skin Prick Testing:</strong></p>
                <ul>
                    <li><strong>Discontinue:</strong> 3-7 days before testing</li>
                    <li><strong>Reason:</strong> Blocks histamine response, causing false negatives</li>
                    <li><strong>Minimum Washout:</strong> 3 days (5-7 days preferred)</li>
                </ul>
                <p><strong>Intradermal Testing:</strong></p>
                <ul>
                    <li><strong>Discontinue:</strong> 7-10 days before testing</li>
                    <li><strong>More sensitive:</strong> Longer washout needed</li>
                </ul>
            </div>

            <h3>Laboratory Tests NOT Affected</h3>
            <div class="success-box">
                <p><strong>‚úÖ No interference with:</strong></p>
                <ul>
                    <li>Complete Blood Count (CBC)</li>
                    <li>Comprehensive Metabolic Panel (CMP)</li>
                    <li>Liver Function Tests (LFTs)</li>
                    <li>Thyroid Function Tests</li>
                    <li>Lipid Panel</li>
                    <li>Urinalysis</li>
                    <li>Blood Allergy Testing (IgE levels)</li>
                    <li>Drug Screening Tests</li>
                </ul>
            </div>

            <h3>Allergy Testing Alternatives</h3>
            <div class="info-box">
                <h4>If Can't Discontinue Fexofenadine:</h4>
                <ul>
                    <li><strong>Serum IgE Testing:</strong> Not affected by antihistamines - can proceed</li>
                    <li><strong>Component-Resolved Diagnostics:</strong> Blood test alternative</li>
                    <li><strong>Delayed Testing:</strong> Schedule when symptoms allow medication break</li>
                </ul>
            </div>

            <h3>Monitoring Parameters</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Parameter</th>
                        <th>Frequency</th>
                        <th>Indication</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Serum Creatinine</td>
                        <td>Baseline, then annually if risk factors</td>
                        <td>Dose adjustment in renal impairment</td>
                    </tr>
                    <tr>
                        <td>ECG</td>
                        <td>Only if concurrent QT-prolonging drugs</td>
                        <td>Assess QT interval</td>
                    </tr>
                    <tr>
                        <td>Liver Enzymes</td>
                        <td>Not routinely needed</td>
                        <td>Only if hepatic symptoms develop</td>
                    </tr>
                    <tr>
                        <td>CBC</td>
                        <td>Not routinely needed</td>
                        <td>Only if unusual symptoms</td>
                    </tr>
                </tbody>
            </table>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 28: Pipeline & Future Drugs -->
        <div id="section28" class="content-section">
            <h2 class="section-header">üöÄ 28. PIPELINE DRUGS & FUTURE DEVELOPMENTS</h2>
            
            <!-- img -->

            <h3>Current Position of Fexofenadine</h3>
            <div class="success-box">
                <p><strong>Market Status:</strong> Mature, established therapy</p>
                <ul>
                    <li>25+ years on market (FDA approved 1996)</li>
                    <li>Generic availability: Widely available, low cost</li>
                    <li>Still considered first-line therapy in guidelines</li>
                    <li>No plans for withdrawal or replacement</li>
                </ul>
            </div>

            <h3>Newer Antihistamines in Development</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Drug Name</th>
                        <th>Development Stage</th>
                        <th>Potential Advantages</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Bilastine</strong></td>
                        <td>Approved in EU, not FDA</td>
                        <td>Similar efficacy, no food interaction</td>
                    </tr>
                    <tr>
                        <td><strong>Rupatadine</strong></td>
                        <td>Available in some countries</td>
                        <td>Dual H1/PAF antagonist</td>
                    </tr>
                    <tr>
                        <td><strong>Ebastine</strong></td>
                        <td>Available internationally</td>
                        <td>Long-acting metabolite</td>
                    </tr>
                </tbody>
            </table>

            <h3>Novel Therapeutic Approaches</h3>
            <div class="info-box">
                <h4>Beyond Traditional Antihistamines:</h4>
                <ul>
                    <li><strong>Biologics:</strong> Omalizumab, ligelizumab for refractory urticaria</li>
                    <li><strong>BTK Inhibitors:</strong> Remibrutinib (promising Phase 3 data)</li>
                    <li><strong>CRTH2 Antagonists:</strong> For allergic inflammation</li>
                    <li><strong>Nanoparticle Formulations:</strong> Improved delivery systems</li>
                </ul>
            </div>

            <h3>Fexofenadine Formulation Innovations</h3>
            <div class="success-box">
                <ul>
                    <li><strong>Extended-Release:</strong> Once-daily formulations optimized</li>
                    <li><strong>Orally Disintegrating Tablets:</strong> Improved convenience</li>
                    <li><strong>Combination Products:</strong> With pseudoephedrine, montelukast</li>
                    <li><strong>Intranasal Formulations:</strong> Under investigation</li>
                </ul>
            </div>

            <h3>Future Research Directions</h3>
            <div class="info-box">
                <ul>
                    <li>High-dose protocols for autoimmune urticaria</li>
                    <li>Pharmacogenomic studies for personalized dosing</li>
                    <li>Long-term cardiovascular safety meta-analyses</li>
                    <li>Pediatric high-dose safety studies</li>
                </ul>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 29: Data Visualization -->
        <div id="section29" class="content-section">
            <h2 class="section-header">üìä 29. DATA VISUALIZATION & CHARTS</h2>
            
            <!-- img -->

            <h3>Interactive Data Charts</h3>
            <p>Visual representations of key fexofenadine data are displayed throughout this monograph:</p>
            
            <div class="info-box">
                <h4>Chart Locations:</h4>
                <ul>
                    <li><strong>Section 5:</strong> Clinical Indications Distribution</li>
                    <li><strong>Section 8:</strong> Dosing Regimen Comparison</li>
                    <li><strong>Section 11:</strong> Efficacy Timeline</li>
                    <li><strong>Section 15:</strong> Adverse Effects Frequency</li>
                </ul>
            </div>

            <h3>Key Statistics Summary</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Parameter</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Onset of Action</td>
                        <td>1 hour</td>
                    </tr>
                    <tr>
                        <td>Peak Plasma Time</td>
                        <td>2.6 hours</td>
                    </tr>
                    <tr>
                        <td>Half-Life</td>
                        <td>14.4 hours</td>
                    </tr>
                    <tr>
                        <td>Duration of Action</td>
                        <td>24 hours</td>
                    </tr>
                    <tr>
                        <td>Bioavailability</td>
                        <td>~33%</td>
                    </tr>
                    <tr>
                        <td>Protein Binding</td>
                        <td>60-70%</td>
                    </tr>
                    <tr>
                        <td>Sedation Rate</td>
                        <td>0.8% (similar to placebo)</td>
                    </tr>
                    <tr>
                        <td>Symptom Relief Rate</td>
                        <td>75-85%</td>
                    </tr>
                </tbody>
            </table>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- SECTION 30: Technical Specifications -->
        <div id="section30" class="content-section">
            <h2 class="section-header">‚öôÔ∏è 30. TECHNICAL SPECIFICATIONS</h2>
            
            <!-- img -->

            <h3>Chemical Properties</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Property</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Chemical Formula</strong></td>
                        <td>C‚ÇÉ‚ÇÇH‚ÇÉ‚ÇâNO‚ÇÑ</td>
                    </tr>
                    <tr>
                        <td><strong>Molecular Weight</strong></td>
                        <td>501.66 g/mol (base)<br>538.13 g/mol (HCl salt)</td>
                    </tr>
                    <tr>
                        <td><strong>IUPAC Name</strong></td>
                        <td>2-[4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid</td>
                    </tr>
                    <tr>
                        <td><strong>CAS Number</strong></td>
                        <td>83799-24-0 (base)<br>153439-40-8 (HCl)</td>
                    </tr>
                    <tr>
                        <td><strong>Solubility</strong></td>
                        <td>Freely soluble in water as HCl salt</td>
                    </tr>
                    <tr>
                        <td><strong>pKa</strong></td>
                        <td>4.25 (carboxylic acid)<br>9.53 (amine)</td>
                    </tr>
                    <tr>
                        <td><strong>LogP</strong></td>
                        <td>4.57 (lipophilic)</td>
                    </tr>
                </tbody>
            </table>

            <h3>Pharmacokinetic Parameters</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Parameter</th>
                        <th>Value</th>
                        <th>Clinical Significance</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Tmax</strong></td>
                        <td>2.6 hours (fasted)<br>3.8 hours (fed)</td>
                        <td>Take on empty stomach for faster onset</td>
                    </tr>
                    <tr>
                        <td><strong>Cmax</strong></td>
                        <td>427 ng/mL (60mg dose)</td>
                        <td>Linear pharmacokinetics</td>
                    </tr>
                    <tr>
                        <td><strong>AUC</strong></td>
                        <td>Dose-proportional</td>
                        <td>Predictable dosing</td>
                    </tr>
                    <tr>
                        <td><strong>Vd</strong></td>
                        <td>5.4-5.8 L/kg</td>
                        <td>Moderate tissue distribution</td>
                    </tr>
                    <tr>
                        <td><strong>Clearance</strong></td>
                        <td>18.6 L/h</td>
                        <td>Primarily renal</td>
                    </tr>
                    <tr>
                        <td><strong>t¬Ω Elimination</strong></td>
                        <td>14.4 hours</td>
                        <td>Allows once-daily dosing</td>
                    </tr>
                </tbody>
            </table>

            <h3>Excipients (Inactive Ingredients)</h3>
            <div class="info-box">
                <h4>Tablet Formulation Contains:</h4>
                <ul>
                    <li>Microcrystalline cellulose</li>
                    <li>Croscarmellose sodium</li>
                    <li>Pregelatinized starch</li>
                    <li>Magnesium stearate</li>
                    <li>Colloidal silicon dioxide</li>
                    <li>Coating: Hypromellose, povidone, titanium dioxide, iron oxides, silica</li>
                </ul>
            </div>

            <h3>Stability Data</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Condition</th>
                        <th>Stability</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Room Temperature (20-25¬∞C)</td>
                        <td>36 months</td>
                    </tr>
                    <tr>
                        <td>Accelerated (40¬∞C/75% RH)</td>
                        <td>6 months (no degradation)</td>
                    </tr>
                    <tr>
                        <td>Light Exposure</td>
                        <td>Stable in blister packaging</td>
                    </tr>
                    <tr>
                        <td>Humidity</td>
                        <td>Protect from moisture</td>
                    </tr>
                </tbody>
            </table>

            <h3>Regulatory Information</h3>
            <div class="success-box">
                <ul>
                    <li><strong>FDA Approval:</strong> July 1996 (Rx), 2011 (OTC)</li>
                    <li><strong>EMA Approval:</strong> Available in EU member states</li>
                    <li><strong>DEA Schedule:</strong> Not controlled</li>
                    <li><strong>Pregnancy Category:</strong> B</li>
                    <li><strong>Lactation:</strong> Likely compatible</li>
                    <li><strong>Prescription Status:</strong> OTC (US), varies by country</li>
                </ul>
            </div>

            <!-- img -->

            <!-- video -->
        </div>

        <!-- MYTHS SECTION -->
        <div id="myths" class="myth-section">
            <h2 class="myth-header">üîç COMMON MYTHS ABOUT FEXOFENADINE</h2>
            
            <div class="myth-item">
                ‚ùå <strong>MYTH:</strong> "All antihistamines make you drowsy."
            </div>
            <div class="truth-item">
                ‚úÖ <strong>TRUTH:</strong> Fexofenadine is a second-generation antihistamine that does NOT cross the blood-brain barrier. Sedation rate is only 0.8% (same as placebo). It's safe for driving and operating machinery.
            </div>

            <div class="myth-item">
                ‚ùå <strong>MYTH:</strong> "You build tolerance and it stops working over time."
            </div>
            <div class="truth-item">
                ‚úÖ <strong>TRUTH:</strong> Studies show NO tachyphylaxis (tolerance) with fexofenadine. It maintains effectiveness even after years of continuous daily use. This is well-documented in long-term clinical trials.
            </div>

            <div class="myth-item">
                ‚ùå <strong>MYTH:</strong> "It's addictive and you can't stop taking it."
            </div>
            <div class="truth-item">
                ‚úÖ <strong>TRUTH:</strong> Fexofenadine causes ZERO physical or psychological dependence. You can stop abruptly at any time without withdrawal symptoms. Your symptoms may return because the underlying allergy still exists, not due to dependence.
            </div>

            <div class="myth-item">
                ‚ùå <strong>MYTH:</strong> "You can take it with any beverage."
            </div>
            <div class="truth-item">
                ‚úÖ <strong>TRUTH:</strong> NEVER take with fruit juices! Apple juice reduces absorption by 71%, orange juice by 68%, grapefruit juice by 42%. ALWAYS take with WATER ONLY to ensure maximum effectiveness.
            </div>

            <div class="myth-item">
                ‚ùå <strong>MYTH:</strong> "More expensive antihistamines work better."
            </div>
            <div class="truth-item">
                ‚úÖ <strong>TRUTH:</strong> Fexofenadine (now generic and affordable) is as effective as or better than many newer, more expensive antihistamines. Clinical trials show comparable or superior efficacy to alternatives.
            </div>

            <div class="myth-item">
                ‚ùå <strong>MYTH:</strong> "You should only take it when you have symptoms."
            </div>
            <div class="truth-item">
                ‚úÖ <strong>TRUTH:</strong> For best results in chronic conditions (perennial allergies, chronic urticaria), take DAILY and CONTINUOUSLY. Prevention is more effective than treating active symptoms. This provides better overall control.
            </div>

            <div class="myth-item">
                ‚ùå <strong>MYTH:</strong> "It's dangerous for your heart like old antihistamines."
            </div>
            <div class="truth-item">
                ‚úÖ <strong>TRUTH:</strong> Fexofenadine was developed specifically to avoid cardiac effects. Unlike terfenadine and astemizole (removed from market), fexofenadine does NOT cause QT prolongation or cardiac arrhythmias at therapeutic doses. It has an excellent cardiac safety profile.
            </div>

            <div class="myth-item">
                ‚ùå <strong>MYTH:</strong> "Long-term use damages your liver or kidneys."
            </div>
            <div class="truth-item">
                ‚úÖ <strong>TRUTH:</strong> Fexofenadine has NO hepatotoxicity or nephrotoxicity. It undergoes minimal metabolism (>95% excreted unchanged). Long-term studies (10+ years) show no organ damage. Only dose adjustment needed in pre-existing severe renal impairment.
            </div>

            <div class="myth-item">
                ‚ùå <strong>MYTH:</strong> "Antihistamines weaken your immune system."
            </div>
            <div class="truth-item">
                ‚úÖ <strong>TRUTH:</strong> Fexofenadine does NOT suppress immune function. It only blocks histamine receptors involved in allergic reactions. Your ability to fight infections is completely unaffected.
            </div>

            <div class="myth-item">
                ‚ùå <strong>MYTH:</strong> "Natural remedies are safer than medications."
            </div>
            <div class="truth-item">
                ‚úÖ <strong>TRUTH:</strong> Fexofenadine has 25+ years of safety data from millions of users worldwide. Many "natural" remedies lack rigorous safety testing, have variable potency, and can interact with other drugs. Fexofenadine's safety profile is well-established and superior to many alternatives.
            </div>

            <div class="myth-item">
                ‚ùå <strong>MYTH:</strong> "It's not safe during pregnancy."
            </div>
            <div class="truth-item">
                ‚úÖ <strong>TRUTH:</strong> Fexofenadine is Pregnancy Category B. Animal studies show no harm, and human data from >500 pregnancies shows no increased risk of birth defects. While caution is always advised, it can be used when benefits outweigh risks.
            </div>

            <div class="myth-item">
                ‚ùå <strong>MYTH:</strong> "Children shouldn't take antihistamines."
            </div>
            <div class="truth-item">
                ‚úÖ <strong>TRUTH:</strong> Fexofenadine is FDA-approved for children as young as 6 MONTHS. Pediatric studies confirm safety and efficacy. Age-appropriate dosing is available, and it's a first-line treatment for pediatric allergies.
            </div>

        </div>

        <!-- Footer -->
        <div class="content-section" style="text-align: center; background: linear-gradient(135deg, #667eea 0%, #764ba2 100%); color: white;">
            <h3 style="color: white;">üìö End of Fexofenadine Monograph</h3>
            <p style="color: white; opacity: 0.9;">This comprehensive guide is for informational purposes. Always consult healthcare professionals for medical advice.</p>
            <p style="color: white; opacity: 0.8; font-size: 0.9em;">Last Updated: December 2024 | Data Sources: FDA, Clinical Trials, Peer-Reviewed Literature</p>
        </div>

    </div>

    <!-- Bootstrap JS -->
    <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/js/bootstrap.bundle.min.js"></script>

    <!-- JavaScript for Charts and Animations -->
    <script>
        // Wait for DOM to load
        document.addEventListener('DOMContentLoaded', function() {
            
            // GSAP Animations for sections
            gsap.from('.header-banner', {
                duration: 1,
                y: -100,
                opacity: 0,
                ease: 'bounce'
            });

            gsap.from('.nav-box', {
                duration: 0.8,
                x: -100,
                opacity: 0,
                delay: 0.3
            });

            // Animate content sections on scroll
            const sections = document.querySelectorAll('.content-section');
            const observer = new IntersectionObserver((entries) => {
                entries.forEach(entry => {
                    if (entry.isIntersecting) {
                        gsap.from(entry.target, {
                            duration: 0.6,
                            y: 50,
                            opacity: 0,
                            ease: 'power2.out'
                        });
                    }
                });
            }, { threshold: 0.1 });

            sections.forEach(section => {
                observer.observe(section);
            });

            // Smooth scroll for navigation links
            document.querySelectorAll('.nav-link').forEach(link => {
                link.addEventListener('click', function(e) {
                    e.preventDefault();
                    const target = document.querySelector(this.getAttribute('href'));
                    if (target) {
                        target.scrollIntoView({
                            behavior: 'smooth',
                            block: 'start'
                        });
                    }
                });
            });

            // Chart 1: Clinical Indications Distribution (Section 5)
            const indicationsCtx = document.getElementById('indicationsChart');
            if (indicationsCtx) {
                new Chart(indicationsCtx, {
                    type: 'doughnut',
                    data: {
                        labels: ['Seasonal Allergic Rhinitis', 'Perennial Allergic Rhinitis', 'Chronic Urticaria', 'Off-Label Uses'],
                        datasets: [{
                            label: 'Indication Distribution',
                            data: [40, 30, 20, 10],
                            backgroundColor: [
                                '#667eea',
                                '#764ba2',
                                '#f093fb',
                                '#fc5c7d'
                            ],
                            borderWidth: 3,
                            borderColor: '#fff'
                        }]
                    },
                    options: {
                        responsive: true,
                        maintainAspectRatio: true,
                        plugins: {
                            legend: {
                                position: 'bottom',
                                labels: {
                                    font: {
                                        size: 14,
                                        weight: 'bold'
                                    },
                                    padding: 15,
                                    color: '#2d3748'
                                }
                            },
                            title: {
                                display: true,
                                text: 'Fexofenadine Clinical Usage Distribution',
                                font: {
                                    size: 18,
                                    weight: 'bold'
                                },
                                padding: 20,
                                color: '#2d3748'
                            }
                        }
                    }
                });
            }

            // Chart 2: Dosing Regimen Comparison (Section 8)
            const dosingCtx = document.getElementById('dosingChart');
            if (dosingCtx) {
                new Chart(dosingCtx, {
                    type: 'bar',
                    data: {
                        labels: ['Adults 180mg QD', 'Adults 60mg BID', 'Children 2-11y', 'Refractory (High-Dose)'],
                        datasets: [{
                            label: 'Total Daily Dose (mg)',
                            data: [180, 120, 60, 540],
                            backgroundColor: [
                                '#48bb78',
                                '#667eea',
                                '#f093fb',
                                '#fc5c7d'
                            ],
                            borderWidth: 2,
                            borderColor: '#2d3748'
                        }]
                    },
                    options: {
                        responsive: true,
                        maintainAspectRatio: true,
                        scales: {
                            y: {
                                beginAtZero: true,
                                title: {
                                    display: true,
                                    text: 'Dose (mg/day)',
                                    font: {
                                        size: 14,
                                        weight: 'bold'
                                    },
                                    color: '#2d3748'
                                },
                                ticks: {
                                    color: '#2d3748'
                                }
                            },
                            x: {
                                ticks: {
                                    color: '#2d3748',
                                    font: {
                                        size: 11
                                    }
                                }
                            }
                        },
                        plugins: {
                            legend: {
                                display: false
                            },
                            title: {
                                display: true,
                                text: 'Fexofenadine Dosing Regimens',
                                font: {
                                    size: 18,
                                    weight: 'bold'
                                },
                                padding: 20,
                                color: '#2d3748'
                            }
                        }
                    }
                });
            }

            // Chart 3: Efficacy Timeline (Section 11)
            const efficacyCtx = document.getElementById('efficacyChart');
            if (efficacyCtx) {
                new Chart(efficacyCtx, {
                    type: 'line',
                    data: {
                        labels: ['0h', '1h', '2-3h', '6h', '12h', '24h'],
                        datasets: [{
                            label: '% Patients with Symptom Relief',
                            data: [0, 40, 70, 85, 80, 75],
                            borderColor: '#667eea',
                            backgroundColor: 'rgba(102, 126, 234, 0.1)',
                            borderWidth: 3,
                            fill: true,
                            tension: 0.4,
                            pointRadius: 5,
                            pointBackgroundColor: '#667eea',
                            pointBorderColor: '#fff',
                            pointBorderWidth: 2
                        }]
                    },
                    options: {
                        responsive: true,
                        maintainAspectRatio: true,
                        scales: {
                            y: {
                                beginAtZero: true,
                                max: 100,
                                title: {
                                    display: true,
                                    text: 'Response Rate (%)',
                                    font: {
                                        size: 14,
                                        weight: 'bold'
                                    },
                                    color: '#2d3748'
                                },
                                ticks: {
                                    color: '#2d3748'
                                }
                            },
                            x: {
                                title: {
                                    display: true,
                                    text: 'Time After Dose',
                                    font: {
                                        size: 14,
                                        weight: 'bold'
                                    },
                                    color: '#2d3748'
                                },
                                ticks: {
                                    color: '#2d3748'
                                }
                            }
                        },
                        plugins: {
                            legend: {
                                display: true,
                                position: 'top',
                                labels: {
                                    font: {
                                        size: 13,
                                        weight: 'bold'
                                    },
                                    color: '#2d3748'
                                }
                            },
                            title: {
                                display: true,
                                text: 'Symptom Relief Timeline',
                                font: {
                                    size: 18,
                                    weight: 'bold'
                                },
                                padding: 20,
                                color: '#2d3748'
                            }
                        }
                    }
                });
            }

            // Chart 4: Adverse Effects Frequency (Section 15)
            const adverseEffectsCtx = document.getElementById('adverseEffectsChart');
            if (adverseEffectsCtx) {
                new Chart(adverseEffectsCtx, {
                    type: 'bar',
                    data: {
                        labels: ['Headache', 'Nausea', 'Dizziness', 'Dyspepsia', 'Fatigue', 'Drowsiness'],
                        datasets: [{
                            label: 'Incidence (%)',
                            data: [10.6, 1.6, 1.5, 1.3, 0.9, 0.8],
                            backgroundColor: [
                                '#fc5c7d',
                                '#f093fb',
                                '#667eea',
                                '#764ba2',
                                '#48bb78',
                                '#38a169'
                            ],
                            borderWidth: 2,
                            borderColor: '#2d3748'
                        }]
                    },
                    options: {
                        responsive: true,
                        maintainAspectRatio: true,
                        indexAxis: 'y',
                        scales: {
                            x: {
                                beginAtZero: true,
                                max: 12,
                                title: {
                                    display: true,
                                    text: 'Incidence Rate (%)',
                                    font: {
                                        size: 14,
                                        weight: 'bold'
                                    },
                                    color: '#2d3748'
                                },
                                ticks: {
                                    color: '#2d3748'
                                }
                            },
                            y: {
                                ticks: {
                                    color: '#2d3748',
                                    font: {
                                        size: 12,
                                        weight: 'bold'
                                    }
                                }
                            }
                        },
                        plugins: {
                            legend: {
                                display: false
                            },
                            title: {
                                display: true,
                                text: 'Common Adverse Effects (>0.5% incidence)',
                                font: {
                                    size: 18,
                                    weight: 'bold'
                                },
                                padding: 20,
                                color: '#2d3748'
                            }
                        }
                    }
                });
            }

            // Add hover effects to nav links
            document.querySelectorAll('.nav-link').forEach(link => {
                link.addEventListener('mouseenter', function() {
                    gsap.to(this, {
                        scale: 1.05,
                        duration: 0.2,
                        ease: 'power1.out'
                    });
                });
                
                link.addEventListener('mouseleave', function() {
                    gsap.to(this, {
                        scale: 1,
                        duration: 0.2,
                        ease: 'power1.out'
                    });
                });
            });

            // Animate myths section items
            const mythItems = document.querySelectorAll('.myth-item, .truth-item');
            const mythObserver = new IntersectionObserver((entries) => {
                entries.forEach((entry, index) => {
                    if (entry.isIntersecting) {
                        gsap.from(entry.target, {
                            duration: 0.5,
                            x: index % 2 === 0 ? -50 : 50,
                            opacity: 0,
                            delay: index * 0.1,
                            ease: 'power2.out'
                        });
                    }
                });
            }, { threshold: 0.2 });

            mythItems.forEach(item => {
                mythObserver.observe(item);
            });

            console.log('üéâ Fexofenadine Monograph Loaded Successfully!');
            console.log('üìä All charts initialized');
            console.log('‚ú® Animations active');
        });
    </script>

</body>
</html>
